51
|
Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton SD, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers (Basel) 2019; 11:cancers11091323. [PMID: 31500210 PMCID: PMC6770064 DOI: 10.3390/cancers11091323] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 08/23/2019] [Accepted: 09/03/2019] [Indexed: 11/16/2022] Open
Abstract
ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation with drug resistance remains unclear. We evaluated ABCB1 activity in relation with clinical parameters and treatment response to standard chemotherapy in 321 patients with de novo AML. We assessed multiple clinical relationships of ABCB1 activity—ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated. ABCB1 activity was observed in 58% of AML and was linked to low white blood cell count, high expression of CD34, absence of FLT3-ITD, and absence of mutant NPM1. Moreover, ABCB1 activity was associated with worse overall- and event-free survival. However, ABCB1 activity did not directly lead to ex vivo drug resistance to anthracyclines. We found that ABCB1 was highly correlated with gene expressions of BAALC, CD34, CD200, and CD7, indicating that ABCB1 expression maybe a passenger characteristic of high-risk AML. Furthermore, ABCB1 was inversely correlated to HOX cluster genes and CD33. Thus, low ABCB1 AML patients benefited specifically from anti-CD33 treatment by gemtuzumab ozogamicin in addition to standard chemotherapy. We showed prognostic importance of ABCB1 gene expression, protein expression, and activity. Furthermore, ABCB1 was not directly linked to drug resistance, ABCB1 inhibition did not improve outcome of high ABCB1 AML patients and thus high ABCB1 may represent a passenger characteristic of high-risk AML.
Collapse
Affiliation(s)
- Thomas Boyer
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Fanny Gonzales
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Adeline Barthélémy
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Alice Marceau-Renaut
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Pauline Peyrouze
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Soizic Guihard
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Pascale Lepelley
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Adriana Plesa
- Laboratory of Hematology, Hospital of Lyon-South, 69495 Pierre - Benite, France
| | - Olivier Nibourel
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Carole Delattre
- Laboratory of Hematology, Hospital of Dunkerque, 59240 Dunkerque, France
| | - Marc Wetterwald
- Department of Hematological Diseases, Hospital of Dunkerque, 59240 Dunkerque, France
| | - Nicolas Pottier
- Department of Biochemistry, University Hospital Lille, 59000 Lille, France
| | - Isabelle Plantier
- Department of Hematological Diseases, Hospital of Roubaix, 59100 Roubaix, France
| | - Stéphane de Botton
- Department of Clinical Hematology, Gustave Roussy Institute, 94800 Paris, France
| | - Hervé Dombret
- Department of Hematology, University Paris 7, 75013 Paris, France
| | - Céline Berthon
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
- Department of Hematological Diseases, University Hospital of Lille, 59000 Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Christophe Roumier
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Meyling Cheok
- Laboratory of Hematology, CHU Lille, 59000 Lille, France.
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France.
| |
Collapse
|
52
|
Coquerelle S, Darlington M, Mezaour N, Preudhomme C, Mc Intyre E, Durand-Zaleski I. Séquençage Haut Débit (NGS) dans les hémopathies malignes et évaluation médico-économique–PRME RUBIH2. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.04.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
53
|
Coquerelle S, Darlington M, Preudhomme C, Mac Intyre E, Durand-Aaleski I. Séquençage haut debit (NGS) et évaluation médico-économique dans les hémopathies malignes : le PRME RUBIH2. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
54
|
Van De Wyngaert Z, Fournier E, Bera E, Carrette M, Soenen V, Gauthier J, Preudhomme C, Boyer T. Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia. Curr Res Transl Med 2019; 68:37-42. [PMID: 30987895 DOI: 10.1016/j.retram.2019.04.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 03/21/2019] [Accepted: 04/02/2019] [Indexed: 01/08/2023]
Affiliation(s)
| | - E Fournier
- Centre de Biologie, Pathologie, Laboratoire d'hématologie, CHU Lille, France; Laboratoire d'Hématologie, Centre Hospitalier de Dunkerque, Dunkerque, France
| | - E Bera
- Laboratoire d'Hématologie, CHU de Rouen, France
| | - M Carrette
- Laboratoire d'Hématologie, CHU de Rouen, France
| | - V Soenen
- Centre de Biologie, Pathologie, Laboratoire d'hématologie, CHU Lille, France
| | - J Gauthier
- Service des Maladies du Sang, CHU Lille, Lille, France
| | - C Preudhomme
- Service des Maladies du Sang, CHU Lille, Lille, France
| | - T Boyer
- Centre de Biologie, Pathologie, Laboratoire d'hématologie, CHU Lille, France.
| |
Collapse
|
55
|
Touzet L, Dumezy F, Roumier C, Berthon C, Bories C, Quesnel B, Preudhomme C, Boyer T. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019; 8:1279-1288. [PMID: 30740913 PMCID: PMC6434215 DOI: 10.1002/cam4.2007] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 12/14/2018] [Accepted: 01/15/2019] [Indexed: 01/04/2023] Open
Abstract
CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute lymphoblastic leukemia (ALL), this marker has not yet been studied in acute myeloid leukemia (AML). First, we explored its prognostic role and its association with biological factors in a cohort of 112 AML patients treated with intensive chemotherapy. CD9 was expressed in 40% of AML and was associated with a favorable outcome (event‐free survival and relapse‐free survival) in univariate (P = 0.009 and P = 0.048, respectively) and multivariate (P = 0.004 and P = 0.039, respectively) analyses. Interestingly, CD9 expression was different between the more immature physiologic and AML cells (CD34+CD38−) as it was also expressed in AML on putative leukemic stem cells (LSCs) but not on hematopoietic stem cells (HSCs). Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting.
Collapse
Affiliation(s)
- Lucas Touzet
- Laboratory of Hematology, CHU Lille, Lille, France
| | | | | | | | | | | | | | - Thomas Boyer
- Laboratory of Hematology, CHU Lille, Lille, France
| |
Collapse
|
56
|
Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica 2019; 104:1565-1571. [PMID: 30733271 PMCID: PMC6669173 DOI: 10.3324/haematol.2018.207118] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 02/07/2019] [Indexed: 11/22/2022] Open
Abstract
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine in high-risk myelodysplastic syndrome and low blast count acute myeloid leukemia patients refractory or relapsing after azacitidine. We included 56 patients with a median age of 75 years [Interquartile Range (IQR) 69-76]. Fifty-five patients received at least one cycle of guadecitabine (60 mg/m2/d subcutaneously days 1-5 per 28-day treatment cycles), with a median of 3 cycles (range, 0-27). Eight (14.3%) patients responded, including two complete responses; median response duration was 11.5 months. Having no or few identified somatic mutations was the only factor predicting response (P=0.035). None of the 11 patients with TP53 mutation responded. Median overall survival was 7.1 months, and 17.9 months in responders (3 of whom had overall survival >2 years). In multivariate analysis, IPSS-R (revised International Prognostic Scoring System) score other than very high (P=0.03) primary versus secondary azacitidine failure (P=0.01) and a high rate of demethylation in blood during the first cycle of treatment (P=0.03) were associated with longer survival. Thus, guadecitabine can be effective, sometimes yielding relatively prolonged survival, in a small proportion of high-risk myelodysplastic syndrome/low blast count acute myeloid leukemia patients who failed azacitidine. (Trial registered at clinicaltrials.gov identifier: 02197676)
Collapse
Affiliation(s)
- Marie Sébert
- Groupe Francophone des Myélodysplasies, Paris, France.,Hématologie Clinique, Hôpital Saint Louis, Paris, France
| | | | - Cécile Bally
- Hématologie Clinique, Hôpital Saint Louis, Paris, France
| | - Pierre Peterlin
- Groupe Francophone des Myélodysplasies, Paris, France.,CHU de Nantes, France
| | - Odile Beyne-Rauzy
- Groupe Francophone des Myélodysplasies, Paris, France.,IUCT ONCOPOLE Toulouse, France
| | - Laurence Legros
- Groupe Francophone des Myélodysplasies, Paris, France.,CHU de Nice, France
| | - Marie-Pierre Gourin
- Groupe Francophone des Myélodysplasies, Paris, France.,CHRU de Limoges, France
| | - Laurence Sanhes
- Groupe Francophone des Myélodysplasies, Paris, France.,CHU de Perpignan, France
| | - Eric Wattel
- Groupe Francophone des Myélodysplasies, Paris, France.,CHU Lyon Sud, Lyon, France
| | - Emmanuel Gyan
- Groupe Francophone des Myélodysplasies, Paris, France.,CHRU de Tours, France
| | - Sophie Park
- Groupe Francophone des Myélodysplasies, Paris, France.,CHU de Grenoble, France
| | - Aspasia Stamatoullas
- Groupe Francophone des Myélodysplasies, Paris, France.,Centre Henri Becquerel, Rouen, France
| | - Anne Banos
- Groupe Francophone des Myélodysplasies, Paris, France.,CH de la Côte Basque, France
| | - Kamel Laribi
- Groupe Francophone des Myélodysplasies, Paris, France.,CHU Côte de Nacre, Caen, France
| | | | - Luke Bevan
- Astex Pharmaceuticals Inc., Cambridge, UK
| | | | - Rosa Sapena
- Groupe Francophone des Myélodysplasies, Paris, France
| | | | - Cendrine Chaffaut
- Service de Biostatistiques, Hôpital Saint-Louis, APHP, Paris, France
| | - Sylvie Chevret
- Service de Biostatistiques, Hôpital Saint-Louis, APHP, Paris, France
| | | | - Lionel Adès
- Groupe Francophone des Myélodysplasies, Paris, France.,Hématologie Clinique, Hôpital Saint Louis, Paris, France
| | - Pierre Fenaux
- Groupe Francophone des Myélodysplasies, Paris, France .,Hématologie Clinique, Hôpital Saint Louis, Paris, France
| | | |
Collapse
|
57
|
Fournier E, Inchiappa L, Delattre C, Pignon JM, Danicourt F, Bemba M, Roche-Lestienne C, Daudignon A, Decool G, Roumier C, Dumezy F, Fournier L, Grardel N, Preudhomme C, Duployez N. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature. Leuk Lymphoma 2019; 60:1827-1830. [DOI: 10.1080/10428194.2018.1562185] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Elise Fournier
- Laboratory of Hematology, CH Dunkerque, Dunkerque, France
- Laboratory of Hematology, CHU Lille, Lille, France
| | | | | | | | | | - Maxime Bemba
- Hematology Department, CH Dunkerque, Dunkerque, France
| | - Catherine Roche-Lestienne
- Department of Medical Genetics, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | | | - Gauthier Decool
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Christophe Roumier
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Florent Dumezy
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Loïc Fournier
- Laboratory of Hematology, CH Dunkerque, Dunkerque, France
| | - Nathalie Grardel
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Nicolas Duployez
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| |
Collapse
|
58
|
Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, Choufi B, Rodriguez C, Frimat C, Plantier I, Stalnikiewicz L, Bemba M, Berthon C, Marolleau JP, Quesnel B, Preudhomme C, Duployez N. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory. Am J Hematol 2019; 94:E24-E27. [PMID: 30358899 DOI: 10.1002/ajh.25328] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 10/17/2018] [Accepted: 10/20/2018] [Indexed: 11/05/2022]
Affiliation(s)
- Loïc Renaud
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | - Olivier Nibourel
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | - Alice Marceau-Renaut
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | | | - Nathalie Cambier
- Department of Hematology; Hôpital St Vincent; Lille France
- Department of Hematology; CH Valenciennes; Valenciennes France
| | | | - Bachra Choufi
- Department of Hematology; CH Boulogne-sur-mer; Boulogne-sur-mer France
| | | | | | | | | | - Maxime Bemba
- Department of Hematology; CH Dunkerque; Dunkerque France
| | - Céline Berthon
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | | | - Bruno Quesnel
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | - Claude Preudhomme
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | - Nicolas Duployez
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| |
Collapse
|
59
|
Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica 2018; 104:1150-1155. [PMID: 30573507 PMCID: PMC6545846 DOI: 10.3324/haematol.2018.208801] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 12/18/2018] [Indexed: 11/30/2022] Open
Abstract
Clonal chromosome abnormalities in Philadelphia-negative cells could concern chronic myeloid leukemia patients treated by tyrosine kinase inhibitors. The European LeukemiaNet distinguishes -7/del(7q) abnormalities as a “warning”. However, the impact of clonal chromosome abnormalities, and specifically those of -7/del(7q), in Philadelphia-negative cells on clinical outcomes is unclear and based on case-reports showing morphological dysplasia and increased risk of acute myeloid leukemia, suggesting the coexistence of chronic myeloid leukemia and high-risk myelodysplastic syndrome. The aim of this study was to determine whether the impact of -7/del(7q) clonal chromosome abnormalities in Philadelphia-negative cells on the clinical outcome is different from that of other types of abnormalities, and we argue for an underlying associated high-risk myelodysplastic syndrome. Among 102 chronic myeloid leukemia patients with clonal chromosome abnormalities in Philadelphia-negative cells with more than a median of 6 years of follow up, patients with -7/del(7q) more frequently had signs of dysplasia, a lower cumulative incidence of deep molecular response and often needed further treatment lines, with the consequent impact on event-free and progression-free survival. Morphological features of dysplasia are associated with myelodysplastic syndrome/acute myeloid leukemia mutations and compromise the optimal response to tyrosine kinase inhibitors, irrespectively of the type of clonal chromosome abnormalities in Philadelphia-negative cells. However, mutation patterns determined by next-generation sequencing could not clearly explain the underlying high-risk disease. We hereby confirm the pejorative prognostic value of -7/del(7q) clonal chromosome abnormalities in Philadelphia-negative cells and suggest that myelodysplastic features constitute a warning signal that response to tyrosine kinase inhibitors may be less than optimal.
Collapse
Affiliation(s)
| | | | - Thomas Smol
- Institut de Génétique Médicale, Hôpital Jeanne de Flandre, CHU Lille.,Centre de Recherche Jean-Pierre Aubert, UMR-S 1172, Université de Lille
| | - Alice Marceau-Renaut
- Institut d'Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille.,Inserm, UMR-S 1172, Lille
| | | | - Valérie Coiteux
- Service des Maladies du Sang, Hôpital Claude Huriez, CHU Lille
| | | | - Franck-Emmanuel Nicolini
- Département d'Hématologie, Centre Léon Bérard, Lyon.,Inserm U1052, Centre de Recherche en Cancérologie, Centre Léon Bérard, Lyon
| | - Isabelle Tigaud
- Laboratoire de Cytogénétique et de Biologie Moléculaire, Service d'Hématologie Biologique - CBPAS, GHS - Hospices Civils de Lyon, Pierre-Bénite Cedex, France
| | - Isabelle Luquet
- Laboratoire d'Hématologie, Plateau Technique Hématologie-Oncologie, Institut Universitaire du Cancer de Tolouse Oncopole
| | - Stéphanie Struski
- Laboratoire d'Hématologie, Plateau Technique Hématologie-Oncologie, Institut Universitaire du Cancer de Tolouse Oncopole
| | | | - Dominique Penther
- Laboratoire de Génétique Oncologique, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen
| | - Sylvie Tondeur
- Laboratoire d'Hématologie-Cytogénétique, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne Cedex 2
| | - Nathalie Nadal
- Laboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, CHU de Dijon
| | - Eric Hermet
- Service d'Hématologie Clinique, CHU Estaing, Clermont-Ferrand
| | | | - Delphine Réa
- Service Clinique des Maladies du Sang, Hôpital St Louis, Paris
| | - Carine Gervais
- Laboratoire Régional de Cytogénétique Hématologique d'Alsace, CHU de Haute Pierre, Strasbourg Cedex
| | - Olivier Theisen
- Laboratoire de Cytogénétique Hématologique, Plateau Technique Hôtel Dieu, Nantes
| | - Christine Terré
- Laboratoire de Cytogénétique du Centre Hospitalier Valence, Le Chesnay
| | | | - Christine Lefebvre
- Unité de Génétique des Hémopathies, Institut de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble Cedex 9
| | | | - Isabelle Radford
- Laboratoire de Cytogénétique, Hôpital Necker - Enfants Malades, Paris
| | | | - Carole Barin
- Laboratoire de Cytogénétique Onco-Hématologie, Hôpital Bretonneau, Tours
| | - Elise Chapiro
- Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris et Sorbonne Université, Paris
| | - Florence Nguyen-Khac
- Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris et Sorbonne Université, Paris
| | - Gabriel Etienne
- Département d'Hématologie, Institut Bergonié, Bordeaux, France
| | - Claude Preudhomme
- Centre de Recherche Jean-Pierre Aubert, UMR-S 1172, Université de Lille.,Institut d'Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille.,Inserm, UMR-S 1172, Lille
| | | | - Catherine Roche-Lestienne
- Institut de Génétique Médicale, Hôpital Jeanne de Flandre, CHU Lille .,Centre de Recherche Jean-Pierre Aubert, UMR-S 1172, Université de Lille.,Inserm, UMR-S 1172, Lille
| | | |
Collapse
|
60
|
Couteau-Chardon A, Groh M, Grardel N, Lefèvre G, Renneville A, Brouzes C, Asnafi V, Cayuela J, Preudhomme C, Kahn J. Étude épidémiologique descriptive française de la leucémie chronique à éosinophiles FIP1L1-PDGFRA +. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
61
|
Couteau-Chardon A, Groh M, Grardel N, Lefèvre G, Renneville A, Preudhomme C, Kahn J. Identification de nouvelles anomalies clonales par séquençage haut débit dans les syndromes hyperéosinophiliques inexpliqués. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
62
|
Duployez N, Preudhomme C, Cheok M. A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia. Oncotarget 2018; 9:33869-33870. [PMID: 30338031 PMCID: PMC6188059 DOI: 10.18632/oncotarget.26116] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Accepted: 09/06/2018] [Indexed: 11/25/2022] Open
Affiliation(s)
- Nicolas Duployez
- Centre Hospitalier Regional Universitaire de Lille, Laboratory of Hematology, Biology and Pathology Center, Lille, France; INSERM, Universitaire de Lille, Jean-Pierre AUBERT Research Center, Lille, France
| | - Claude Preudhomme
- Centre Hospitalier Regional Universitaire de Lille, Laboratory of Hematology, Biology and Pathology Center, Lille, France; INSERM, Universitaire de Lille, Jean-Pierre AUBERT Research Center, Lille, France
| | - Meyling Cheok
- Centre Hospitalier Regional Universitaire de Lille, Laboratory of Hematology, Biology and Pathology Center, Lille, France; INSERM, Universitaire de Lille, Jean-Pierre AUBERT Research Center, Lille, France
| |
Collapse
|
63
|
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2018; 104:113-119. [PMID: 30076173 PMCID: PMC6312010 DOI: 10.3324/haematol.2018.188888] [Citation(s) in RCA: 199] [Impact Index Per Article: 33.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Accepted: 07/25/2018] [Indexed: 11/23/2022] Open
Abstract
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (AML). Here we report an independent review of EFS, final overall survival (OS), and additional safety results from ALFA-0701. Patients (n=271) aged 50-70 years with de novo AML were randomized to receive conventional front-line induction chemotherapy (3+7daunorubicin+cytarabine) with/without gemtuzumab ozogamicin 3 mg/m2 on days 1, 4, and 7 during induction. Patients in remission following induction therapy received 2 courses of consolidation therapy (daunorubicin+cytarabine) with/without gemtuzumab ozogamicin (3 mg/m2/day on day 1) according to their initial randomization. The primary end point was investigator-assessed EFS. Secondary end points included OS and safety. A blinded independent review confirmed the investigator-assessed EFS results [August 1, 2011; hazard ratio (HR) 0.66; 95% Confidence Interval (CI): 0.49–0.89; 2-sided P=0.006], corresponding to a 34% reduction in risk of events in the gemtuzumab ozogamicin versus control arm. Final OS at April 30, 2013 favored gemtuzumab ozogamicin but was not significant. No differences in early death rate were observed between arms. The main toxicity associated with gemtuzumab ozogamicin was prolonged thrombocytopenia. Veno-occlusive disease (including after transplant) was observed in 6 patients in the gemtuzumab ozogamicin arm and 2 in the control arm. In conclusion, gemtuzumab ozogamicin added to standard intensive chemotherapy has a favorable benefit/risk ratio. These results expand front-line treatment options for adult patients with previously untreated AML. (Trial registered at clinicaltrials.gov; identifier: 00927498.)
Collapse
Affiliation(s)
- Juliette Lambert
- Service d'Hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France
| | - Cécile Pautas
- Service d'Hématologie et de Thérapie Cellulaire, Hôpital Henri Mondor, Créteil, France
| | - Christine Terré
- Laboratoire de Cytogénétique, Centre Hospitalier de Versailles, France
| | | | - Pascal Turlure
- Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire, Limoges, France
| | - Denis Caillot
- Hematologie Clinique, Hôpital François Mitterrand, Centre Hospitalier Universitaire, Dijon, France
| | - Ollivier Legrand
- Hôpital Saint-Antoine (AP-HP), Université Paris Pierre et Marie Curie, France
| | - Xavier Thomas
- Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Lyon 1, Pierre Benite, France
| | - Claude Gardin
- Hôpital Avicenne (AP-HP), Université Paris 13, Bobigny, France
| | | | - Stephen D Rubin
- Global Product Development, Pfizer Inc., Collegeville, PA, USA
| | | | | | - Claude Preudhomme
- Université Lille, INSERM, Centre Hospitalier Universitaire Lille, UMR-S 1172 - Jean-Pierre Aubert Center - Centre de Recherche, Lille, France
| | - Sylvie Chevret
- Departement de Biostatistique, Hôpital Saint-Louis (AP-HP), Universite Paris Diderot, INSERM S 717, France
| | - Herve Dombret
- Hopital Saint-Louis (AP-HP), Universite Paris Diderot, France
| | - Sylvie Castaigne
- Service d'Hématologie et Oncologie, Centre Hospitalier de Versailles, Université de Versailles Saint Quentin, Le Chesnay, France
| |
Collapse
|
64
|
Duployez N, Chebrek L, Helevaut N, Fournier E, Bemba M, Caillault A, Geffroy S, Preudhomme C. A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. Haematologica 2018; 103:e575-e577. [PMID: 29903763 DOI: 10.3324/haematol.2018.190959] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Nicolas Duployez
- CHU Lille, Laboratory of Hematology .,Univ. Lille, INSERM, UMR-S 1172
| | | | - Nathalie Helevaut
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| | - Elise Fournier
- Univ. Lille, INSERM, UMR-S 1172.,CH Dunkerque, Laboratory of Hematology, F-59385
| | - Maxime Bemba
- CH Dunkerque, Hematology Department, F-59385, France
| | | | - Sandrine Geffroy
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| | - Claude Preudhomme
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| |
Collapse
|
65
|
Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L. NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. Haematologica 2018; 103:e455-e457. [PMID: 29748442 DOI: 10.3324/haematol.2018.189886] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
| | - Cécile Bally
- Hématologie Clinique, Hôpital Saint Louis, Paris, France
| | | | - Christian Recher
- Clinical Hematology, IUCT Oncopole, Toulouse University Hospital, France
| | | | | | | | - Arnaud Pigneux
- Hematology Department, Centre Hospitalier Universitaire (CHU) de Bordeaux, Universités de Bordeaux, France
| | | | - Judith Desoutter
- Laboratoire d'Hématologie, CHRU Lille, Université de Lille, France
| | - Julie Gay
- Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Claude Preudhomme
- Centre de Biologie-Pathologie, Centre Hospitalier Universitaire de Lille, France
| | | | - Lionel Adès
- Hématologie Clinique, Hôpital Saint Louis, Paris, France
| |
Collapse
|
66
|
Donadieu J, Lamant M, Fieschi C, de Fontbrune FS, Caye A, Ouachee M, Beaupain B, Bustamante J, Poirel HA, Isidor B, Van Den Neste E, Neel A, Nimubona S, Toutain F, Barlogis V, Schleinitz N, Leblanc T, Rohrlich P, Suarez F, Ranta D, Chahla WA, Bruno B, Terriou L, Francois S, Lioure B, Ahle G, Bachelerie F, Preudhomme C, Delabesse E, Cave H, Bellanné-Chantelot C, Pasquet M. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica 2018; 103:1278-1287. [PMID: 29724903 PMCID: PMC6068047 DOI: 10.3324/haematol.2017.181909] [Citation(s) in RCA: 107] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Accepted: 04/27/2018] [Indexed: 12/18/2022] Open
Abstract
Heterozygous germline GATA2 mutations strongly predispose to leukemia, immunodeficiency, and/or lymphoedema. We describe a series of 79 patients (53 families) diagnosed since 2011, made up of all patients in France and Belgium, with a follow up of 2249 patients/years. Median age at first clinical symptoms was 18.6 years (range, 0-61 years). Severe infectious diseases (mycobacteria, fungus, and human papilloma virus) and hematologic malignancies were the most common first manifestations. The probability of remaining symptom-free was 8% at 40 years old. Among the 53 probands, 24 had missense mutations including 4 recurrent alleles, 21 had nonsense or frameshift mutations, 4 had a whole-gene deletion, 2 had splice defects, and 2 patients had complex mutations. There were significantly more cases of leukemia in patients with missense mutations (n=14 of 34) than in patients with nonsense or frameshift mutations (n=2 of 28). We also identify new features of the disease: acute lymphoblastic leukemia, juvenile myelomonocytic leukemia, fatal progressive multifocal leukoencephalopathy related to the JC virus, and immune/inflammatory diseases. A revised International Prognostic Scoring System (IPSS) score allowed a distinction to be made between a stable disease and hematologic transformation. Chemotherapy is of limited efficacy, and has a high toxicity with severe infectious complications. As the mortality rate is high in our cohort (up to 35% at the age of 40), hematopoietic stem cell transplantation (HSCT) remains the best choice of treatment to avoid severe infectious and/or hematologic complications. The timing of HSCT remains difficult to determine, but the earlier it is performed, the better the outcome.
Collapse
Affiliation(s)
- Jean Donadieu
- Department of Paediatric Haematology and Oncology, Registre National des Neutropénies Chroniques, AP-HP Trousseau Hospital, Paris, France
| | - Marie Lamant
- Department of Paediatric Haematology and Immunology, CHU Toulouse, France
| | - Claire Fieschi
- Department of Clinical Immunology Assistance Publique - Hôpitaux de Paris (AP-HP) Saint-Louis Hospital, France.,INSERM UMR1126, Centre Hayem, Université Paris Denis Diderot, Sorbonne Paris Cité, France
| | - Flore Sicre de Fontbrune
- Department of Haematology and Bone Marrow Transplantation, AP-HP Saint-Louis Hospital, Paris, France
| | - Aurélie Caye
- Genetic Laboratory, AP-HP Robert Debré Hospital, Paris, France
| | - Marie Ouachee
- Department of Haematology, AP-HP Robert Debré Hospital, Paris, France
| | - Blandine Beaupain
- French Neutropenia Registry, AP-HP Trousseau Hospital, Paris, France
| | - Jacinta Bustamante
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Necker-Enfants Malades Hospital, Paris, France.,Centre for the Study of Primary Immunodeficiencies, Necker-Enfants Malades Hospital, AP-HP, Paris, France.,St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, New York, NY, USA.,Paris Descartes University, Imagine Institute, Paris, France
| | - Hélène A Poirel
- Centre for Human Genetics, Cliniques Universitaires Saint-Luc & Human Molecular Genetics (GEHU), de Duve Institute -Université Catholique de Louvain, Brussels, Belgium
| | | | | | - Antoine Neel
- Department of Internal Medicine, CHU Nantes, France
| | | | - Fabienne Toutain
- Department of Paediatric Haematology and Oncology, CHU de Rennes, France
| | - Vincent Barlogis
- Department of Paediatric Haematology, CHU de Marseille, Hopital La Timone, Université Aix-Marseille, France
| | - Nicolas Schleinitz
- Internal Medicine, CHU de Marseille, Hopital La Timone, Université Aix-Marseille, France
| | - Thierry Leblanc
- Department of Haematology, AP-HP Robert Debré Hospital, Paris, France
| | | | - Felipe Suarez
- Department of Haematology, AP-HP Necker-Enfants Malades, INSERM UMR 1163 and CNRS ERL 8254 Institut Imagine, Sorbonne Paris Cité, Université Paris Descartes, France
| | - Dana Ranta
- Department of Haematology, CHU de Nancy, France
| | | | | | - Louis Terriou
- Department of Internal Medicine and Immunology, CHU Lille, France
| | | | - Bruno Lioure
- Department of Haematology, CHU de Strasbourg, France
| | - Guido Ahle
- Department of Neurology, Hôpitaux Civils de Colmar, France
| | - Françoise Bachelerie
- Inflammation Chimiokines et Immunopathologie, INSERM, Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Clamart, France
| | | | - Eric Delabesse
- Laboratory of Haematology, IUCT-Oncopole, Toulouse, France.,Centre of Research in Oncology, INSERM U1037, Team 16, IUCT-Oncopole, Toulouse, France
| | - Hélène Cave
- Genetic Laboratory, AP-HP Robert Debré Hospital, Paris, France
| | - Christine Bellanné-Chantelot
- Department of Genetics, AP-HP Pitié Salpêtrière Hospital, Faculté de Médecine Sorbonne Université, Paris, France
| | - Marlène Pasquet
- Department of Paediatric Haematology and Immunology, CHU Toulouse, France .,Centre of Research in Oncology, INSERM U1037, Team 16, IUCT-Oncopole, Toulouse, France
| | | |
Collapse
|
67
|
Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine 2018; 31:174-181. [PMID: 29728305 PMCID: PMC6013781 DOI: 10.1016/j.ebiom.2018.04.018] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 04/20/2018] [Indexed: 12/02/2022] Open
Abstract
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated with a median of 7 cycles of azacitidine (n = 68) or decitabine (n = 106). Sequencing data before treatment initiation were available for all patients, from Sanger (n = 68) or next generation (n = 106) sequencing. Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%). In multivariate analysis, ASXL1 mutations predicted a lower ORR (Odds Ratio [OR] = 0.85, p = 0.037), whereas TET2mut/ASXL1wt genotype predicted a higher CR rate (OR = 1.18, p = 0.011) independently of clinical parameters. With a median follow-up of 36.7 months, overall survival (OS) was 23.0 months. In multivariate analysis, RUNX1mut (Hazard Ratio [HR] = 2.00, p = .011), CBLmut (HR = 1.90, p = 0.03) genotypes and higher WBC (log10(WBC) HR = 2.30, p = .005) independently predicted worse OS while the TET2mut/ASXL1wt predicted better OS (HR = 0.60, p = 0.05). CMML-specific scores CPSS and GFM had limited predictive power. Our results stress the need for robust biomarkers of HMA activity in CMML and for novel treatment strategies in patients with myeloproliferative features and RUNX1 mutations. TET2mut/ASXL1wt genotype predicts higher complete response rate and prolonged survival in CMML with hypomethylating agents. Conversely, RUNX1mut and CBLmut genotypes are associated with poorer outcome, independently of higher leukocyte count. CPSS and GFM prognostic scores showed modest performance when calculated at initiation of hypomethylating agents.
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML. Response and survival in MDS and AML patients treated with HMAs is difficult to predict. We explore the predictive role of recurrent somatic mutations in a large retrospective cohort of 174 HMA-treated CMMLs. Consistent with MDS studies, we report a higher response rate in TET2mut/ASXL1wt patients. We also identify a CMML-specific molecular pattern (RUNX1mut or CBLmut) associated with shorter survival. Our results can inform treatment decision in CMML, for instance by using HMAs prior to transplant in TET2mut/ASXL1wt patients.
Collapse
Affiliation(s)
| | | | - Alessandro Sanna
- MDS Unit-Hematology, Università di Firenze AOU careggi, Firenze, Italy
| | - David Sallman
- Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Catherine C Coombs
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Aline Renneville
- Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - Olivier Kosmider
- Laboratory of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Thorsten Braun
- Department of Hematology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - Uwe Platzbecker
- Department of Hematology and Oncology, University Hospital Carl Gustav Carus, Dresden, Germany
| | - Lise Willems
- Department of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Lionel Adès
- Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France
| | - Michaela Fontenay
- Laboratory of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Raajit Rampal
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Eric Padron
- Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Nathalie Droin
- INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France
| | - Claude Preudhomme
- Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - Valeria Santini
- MDS Unit-Hematology, Università di Firenze AOU careggi, Firenze, Italy
| | | | - Pierre Fenaux
- Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France
| | - Eric Solary
- INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Department of Hematology, Gustave Roussy Cancer Center, University Paris Sud, Villejuif, France
| | - Raphael Itzykson
- Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France; INSERM/CNRS UMR 944/7212, Saint-Louis Institute, Paris, France.
| |
Collapse
|
68
|
Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P. Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia 2018; 32:2066-2069. [PMID: 29740159 DOI: 10.1038/s41375-018-0137-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Revised: 03/18/2018] [Accepted: 04/04/2018] [Indexed: 01/15/2023]
Affiliation(s)
- Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, Lille, France
| | - Philippe Attias
- Service d'Hématologie Seniors, Saint-Louis Hospital, AP-HP, Paris, France
| | - Xavier Thomas
- Hematology Department, Lyon Sud Hospital, Pierre Bénite, France
| | - Cécile Bally
- Service d'Hématologie Seniors, Saint-Louis Hospital, AP-HP, Paris, France
| | | | - Hassan Farhat
- Hematology Department, André Mignot Hospital, Le Chesnay, France
| | - Virginie Eclache
- Hematology Laboratory, Avicenne Hospital, AP-HP, Bobigny, France
| | | | - Bruno Cassinat
- Service de Biologie Cellulaire, Saint-Louis Hospital, AP-HP, Paris, France
| | | | - Christine Terré
- Hematology Laboratory, Andre Mignot Hospital, Le Chesnay, France
| | - Eric Delabesse
- Institut Universitaire de Cancérologie de Toulouse, CHU de Toulouse, Toulouse, France
| | - Sophie Park
- Hematology Department, CHU Grenoble Alpes, Grenoble, France
| | - Julie Lejeune
- Biostatistic Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - Sylvie Chevret
- Biostatistic Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - Lionel Adès
- Service d'Hématologie Seniors, Saint-Louis Hospital, AP-HP, Paris, France
| | | | - Pierre Fenaux
- Service d'Hématologie Seniors, Saint-Louis Hospital, AP-HP, Paris, France. .,Groupe Français des myélodysplasies (GFM), Paris, France.
| |
Collapse
|
69
|
Boyer T, Gonzales F, Plesa A, Peyrouze P, Barthelemy A, Guihard S, Quesnel B, Roumier C, Preudhomme C, Cheok M. Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. J Vis Exp 2018. [PMID: 29630051 DOI: 10.3791/56976] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous, and if not treated, fatal disease. It is the most common cause of leukemia-associated mortality in adults. Initially, AML is a disease of hematopoietic stem cells (HSC) characterized by arrest of differentiation, subsequent accumulation of leukemia blast cells, and reduced production of functional hematopoietic elements. Heterogeneity extends to the presence of leukemia stem cells (LSC), with this dynamic cell compartment evolving to overcome various selection pressures imposed upon during leukemia progression and treatment. To further define the LSC population, the addition of CD90 and CD45RA allows the discrimination of normal HSCs and multipotent progenitors within the CD34+CD38- cell compartment. Here, we outline a protocol to detect simultaneous expression of several putative LSC markers (CD34, CD38, CD45RA, CD90) on primary blast cells of human AML by multiparametric flow cytometry. Furthermore, we show how to quantify three progenitor populations and a putative LSC population with increasing degree of maturation. We confirmed the presence of these populations in corresponding patient-derived-xenografts. This method of detection and quantification of putative LSC may be used for clinical follow-up of chemotherapy response (i.e., minimal residual disease), as residual LSC may cause AML relapse.
Collapse
Affiliation(s)
- Thomas Boyer
- Laboratoire d'hématologie, CHU Lille; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Fanny Gonzales
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer; Service d'hématologie pédiatrique, hôpital Jeanne de Flandre, CHU Lille
| | | | - Pauline Peyrouze
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Adeline Barthelemy
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Soizic Guihard
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Bruno Quesnel
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer; Service des Maladies du Sang, hôpital Claude Huriez, CHU Lille
| | - Christophe Roumier
- Laboratoire d'hématologie, CHU Lille; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Claude Preudhomme
- Laboratoire d'hématologie, CHU Lille; Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer
| | - Meyling Cheok
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer;
| |
Collapse
|
70
|
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131:1275-1291. [PMID: 29330221 PMCID: PMC5865231 DOI: 10.1182/blood-2017-09-801498] [Citation(s) in RCA: 738] [Impact Index Per Article: 123.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 01/03/2018] [Indexed: 12/13/2022] Open
Abstract
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.
Collapse
Affiliation(s)
- Gerrit J Schuurhuis
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - Sylvie Freeman
- Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
| | | | - Francesco Buccisano
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Jacqueline Cloos
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
- Department of Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands
| | - David Grimwade
- Division of Genetics & Molecular Medicine, King's College, London, United Kingdom
| | | | - Robert K Hills
- Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
| | | | - Jeffrey L Jorgensen
- Division of Pathology/Laboratory Medicine, Department of Hematopathology, MD Anderson Cancer Center, Houston, TX
| | | | - Francis Lacombe
- Flow Cytometry Platform, University Hospital, Bordeaux, France
| | - Luca Maurillo
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Claude Preudhomme
- Center of Pathology, Laboratory of Hematology, University Hospital of Lille, Lille, France
| | - Bert A van der Reijden
- Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Christian Thiede
- Universitätsklinikum Carl Gustav Garus an der Technischen Universität Dresden, Dresden, Germany
| | - Adriano Venditti
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Paresh Vyas
- Medical Research Council Molecular Haematology Unit, Oxford Centre for Haematology, University of Oxford and Oxford University Hospitals National Health Service Trust, Oxford, United Kingdom
| | - Brent L Wood
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
- Department of Laboratory Medicine and
| | - Roland B Walter
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
- Division of Hematology, Department of Medicine, University of Washington, Seattle, WA
| | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; and
| | - Gail J Roboz
- Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
| | - Gert J Ossenkoppele
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
71
|
Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet 2018; 26:314-323. [PMID: 29367707 PMCID: PMC5838982 DOI: 10.1038/s41431-017-0081-3] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 11/21/2017] [Accepted: 12/05/2017] [Indexed: 12/25/2022] Open
Abstract
It is currently unclear if next-generation sequencing (NGS) technologies can be implemented in the diagnosis setting at an affordable cost. The aim of this study was to measure the total cost of performing NGS in clinical practice in France, in both germline and somatic cancer genetics.The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. In addition, we used a top-down methodology for specific post-sequencing steps including bioinformatics, technical validation, and biological validation. Additional non-specific costs were also included. Costs were detailed per step of the process (from the pre-analytical phase to delivery of results), and per cost driver (consumables, staff, equipment, maintenance, overheads). Sensitivity analyses were performed.The mean total cost of NGS for targeted gene panels was estimated to 607€ (±207) in somatic genetics and 550€ (±140) in germline oncogenetic analysis. Consumables were the highest cost driver of the sequencing process. The sensitivity analysis showed that a 25% reduction of consumables resulted in a 15% decrease in total NGS cost in somatic genetics, and 13% in germline analysis. Additional costs accounted for 30-32% of the total NGS costs.Beyond cost assessment considerations, the diffusion of NGS technologies will raise questions about their efficiency when compared to more targeted approaches, and their added value in a context of routine diagnosis.
Collapse
Affiliation(s)
- Patricia Marino
- Institut Paoli Calmettes, SESSTIM, Marseille, France.
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Univ, Marseille, France.
| | - Rajae Touzani
- Institut Paoli Calmettes, SESSTIM, Marseille, France
- INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Univ, Marseille, France
| | - Lionel Perrier
- Léon Berard Cancer Centre, GATE L-SE, UMR-CNRS 5824, Lyon, France
| | - Etienne Rouleau
- Department of Pathology and Medical Biology, Gustave Roussy, Villejuif, France
| | | | - Zou Zhaomin
- Gustave Roussy, Etudes et Recherche en économie de la santé, Villejuif, France
| | | | - Nicolas Goardon
- Cancer Comprehensive Center François Baclesse, Cancer Biology and Genetics Laboratory, Caen, France
| | - Claude Preudhomme
- CHRU of Lille, Biology & Pathology Center, Laboratory of Hematology, Lille, France
| | | | - Isabelle Borget
- Gustave Roussy, Etudes et Recherche en économie de la santé, Villejuif, France
| | | |
Collapse
|
72
|
Ali A, Penneroux J, Dal Bello R, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia 2018. [PMID: 29535430 DOI: 10.1038/s41375-018-0076-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Ashfaq Ali
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France
| | - Justine Penneroux
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France
| | - Reinaldo Dal Bello
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Hematology Department, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France.,Hematology Department, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Aline Massé
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France
| | - Samuel Quentin
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Laboratory of Hematology, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Ashwin Unnikrishnan
- Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2025, Australia
| | - Lucie Hernandez
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Laboratory of Hematology, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Emmanuel Raffoux
- Hematology Department, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Raouf Ben Abdelali
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Laboratory of Hematology, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - Claude Preudhomme
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - John Pimanda
- Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2025, Australia
| | - Hervé Dombret
- Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Hematology Department, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Jean Soulier
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Laboratory of Hematology, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Pierre Fenaux
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Hematology Department, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Emmanuelle Clappier
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Laboratory of Hematology, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Lionel Adès
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France.,Hematology Department, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France
| | - Alexandre Puissant
- INSERM/CNRS UMR 944/7212, Paris, France.,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France
| | - Raphael Itzykson
- INSERM/CNRS UMR 944/7212, Paris, France. .,Institut Universitaire d'Hématologie, Paris Cancer Research Institute (PACRI), Université Paris Diderot, Paris, France. .,Hematology Department, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, University Paris Diderot, Paris, France.
| |
Collapse
|
73
|
Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica 2018; 103:822-829. [PMID: 29472349 PMCID: PMC5927984 DOI: 10.3324/haematol.2017.183525] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Accepted: 02/16/2018] [Indexed: 12/27/2022] Open
Abstract
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia, since these mutations collectively occur in 15–20% of cases of acute myeloid leukemia and now represent druggable targets. We employed droplet digital polymerase chain reaction assays to quantify IDH1R132, IDH2R140, and IDH2R172 mutations on genomic DNA in 322 samples from 103 adult patients with primary IDH1/2 mutant acute myeloid leukemia and enrolled on Acute Leukemia French Association (ALFA) - 0701 or -0702 clinical trials. The median IDH1/2 mutant allele fraction in bone marrow samples was 42.3% (range, 8.2 – 49.9%) at diagnosis of acute myeloid leukemia, and below the detection limit of 0.2% (range, <0.2 – 39.3%) in complete remission after induction therapy. In univariate analysis, the presence of a normal karyotype, a NPM1 mutation, and an IDH1/2 mutant allele fraction <0.2% in bone marrow after induction therapy were statistically significant predictors of longer disease-free survival. In multivariate analysis, these three variables remained significantly predictive of disease-free survival. In 7/103 (7%) patients, IDH1/2 mutations persisted at high levels in complete remission, consistent with the presence of an IDH1/2 mutation in pre-leukemic hematopoietic stem cells. Five out of these seven patients subsequently relapsed or progressed toward myelodysplastic syndrome, suggesting that patients carrying the IDH1/2 mutation in a pre-leukemic clone may be at high risk of hematologic evolution.
Collapse
Affiliation(s)
- Yann Ferret
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Nicolas Boissel
- Hematology Department, Saint-Louis Hospital, AP-HP, Paris, France.,EA3518, Institut Universitaire d'Hématologie (IUH), University 7 Paris Diderot, Paris, France
| | - Nathalie Helevaut
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
| | - Jordan Madic
- Circulating Biomarkers Laboratory, Curie Institute, Paris, France
| | - Olivier Nibourel
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Alice Marceau-Renaut
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Maxime Bucci
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
| | - Sandrine Geffroy
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
| | - Karine Celli-Lebras
- Acute Leukemia French Association (ALFA) coordination, Saint-Louis Hospital, AP-HP, Paris, France
| | | | - Xavier Thomas
- Hematology Department, Lyon Sud Hospital, Pierre Benite, France
| | - Christine Terré
- Cytogenetic Laboratory, Versailles Hospital, Le Chesnay, France
| | - Hervé Dombret
- Hematology Department, Saint-Louis Hospital, AP-HP, Paris, France.,EA3518, Institut Universitaire d'Hématologie (IUH), University 7 Paris Diderot, Paris, France
| | - Claude Preudhomme
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France .,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| |
Collapse
|
74
|
Duployez N, Abou Chahla W, Lejeune S, Marceau-Renaut A, Letizia G, Boyer T, Geffroy S, Peyrouze P, Grardel N, Nelken B, Michel G, Bertrand Y, Preudhomme C. Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. Eur J Haematol 2018; 100:104-107. [PMID: 29034503 DOI: 10.1111/ejh.12981] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2017] [Indexed: 02/01/2023]
Abstract
ETV6 is a target of recurrent aberrations in sporadic and familial acute lymphoblastic leukemia (ALL). Here, we report on a new pedigree with a germline ETV6 mutation in which the index patient and his father developed high hyperdiploid (HeH) ALL and polycythemia vera at age 13 and 51, respectively. The index patient achieved durable complete remission without transplantation but had persistent moderate thrombocytopenia without bleeding tendency. To determine the prevalence of ETV6 alterations in HeH-ALL, we screened 81 unrelated subjects with HeH-ALL by single nucleotide polymorphism array and high-throughput sequencing for the ETV6 gene. Overall, ETV6 microdeletions and mutations were identified in 9% of cases, all of which were somatic and considered as secondary events. Apart from the index patient, no germline ETV6 aberration was identified. Finally, we reviewed the literature for ETV6 germline aberrations and predispositions to ALL.
Collapse
Affiliation(s)
- Nicolas Duployez
- Laboratory of Hematology, CHU Lille, Lille, France
- UMR-S 1172, INSERM, Lille, France
| | | | - Sophie Lejeune
- Department of Clinical Genetics, CHU Lille, Lille, France
| | - Alice Marceau-Renaut
- Laboratory of Hematology, CHU Lille, Lille, France
- UMR-S 1172, INSERM, Lille, France
| | - Guillaume Letizia
- CH Boulogne-Sur-Mer, Laboratory of Hematology, Boulogne-Sur-Mer, France
| | - Thomas Boyer
- Laboratory of Hematology, CHU Lille, Lille, France
- UMR-S 1172, INSERM, Lille, France
| | - Sandrine Geffroy
- Laboratory of Hematology, CHU Lille, Lille, France
- UMR-S 1172, INSERM, Lille, France
| | | | | | - Brigitte Nelken
- Department of Pediatric Hematology, CHU Lille, Lille, France
| | - Gérard Michel
- Department of Pediatric Hematology, CHU Marseille La Timone, Marseille, France
| | - Yves Bertrand
- IHOP, Hospices Civils de Lyon and Claude Bernard University, Lyon, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, Lille, France
- UMR-S 1172, INSERM, Lille, France
| |
Collapse
|
75
|
|
76
|
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol 2017; 36:422-428. [DOI: 10.1002/hon.2488] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/13/2017] [Accepted: 11/06/2017] [Indexed: 01/17/2023]
Affiliation(s)
| | - Lydia Campos
- Hematology Biology; University Hospital; Saint Etienne France
| | - Kaoutar Allou
- Hematology Biology; University Hospital; Bordeaux France
| | | | | | | | | | | | | | - Julien Guy
- Hematology Biology; University Hospital; Dijon France
| | | | | | - Marc Maynadié
- Hematology Biology; University Hospital; Dijon France
| | - Françoise Solly
- Hematology Biology; University Hospital; Saint Etienne France
| | | | | | - André Baruchel
- Hematology Department; Hôpital Robert Debré; Paris France
| | - Hervé Dombret
- Hematology Department; Hôpital Saint Louis; Paris France
| | - Norbert Ifrah
- Hematology Department; University Hospital; Angers France
| | - Marie C. Béné
- Hematology Biology; University Hospital; Nantes France
| | | |
Collapse
|
77
|
Vial Y, Lachenaud J, Verloes A, Besnard M, Fenneteau O, Lainey E, Marceau-Renaut A, Preudhomme C, Baruchel A, Cavé H, Drunat S. Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. Haematologica 2017; 103:e274-e276. [PMID: 29217785 DOI: 10.3324/haematol.2017.178590] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Affiliation(s)
- Yoann Vial
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Département de Génétique, France.,Université Paris Diderot, Paris Sorbonne Cité, France.,INSERM UMR 1131, Institut Universitaire d'Hématologie, Paris, France
| | - Julie Lachenaud
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Hématologie Pédiatrique, France
| | - Alain Verloes
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Département de Génétique, France.,Université Paris Diderot, Paris Sorbonne Cité, France.,INSERM UMR 1141, Hôpital Robert Debré, Paris, France
| | - Marianne Besnard
- Centre Hospitalier de Polynésie Française (CHPF), Service de Réanimation néonatale et Néonatologie, Papeete, Tahiti
| | - Odile Fenneteau
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Hématologie Biologique, France
| | - Elodie Lainey
- Université Paris Diderot, Paris Sorbonne Cité, France.,INSERM UMR 1131, Institut Universitaire d'Hématologie, Paris, France.,Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Hématologie Biologique, France
| | | | - Claude Preudhomme
- CHU Lille, Laboratoire d'hématologie, France.,INSERM, UMR-S 1172, France
| | - André Baruchel
- Université Paris Diderot, Paris Sorbonne Cité, France.,Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Hématologie Pédiatrique, France
| | - Hélène Cavé
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Département de Génétique, France.,Université Paris Diderot, Paris Sorbonne Cité, France.,INSERM UMR 1131, Institut Universitaire d'Hématologie, Paris, France
| | - Séverine Drunat
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Département de Génétique, France .,INSERM UMR 1141, Hôpital Robert Debré, Paris, France
| |
Collapse
|
78
|
Zawadzki C, Gaveriaux V, Trillot N, Bauters A, Watel A, Alhenc-Gelas M, Preudhomme C, Jude B. Homozygous G20210A Transition in the Prothrombin Gene Associated with Severe Venous Thrombotic Disease: Two Cases in a French Family. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615406] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
79
|
Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X. Role of IRF4 in resistance to immunomodulatory (IMid) compounds ® in Waldenström's macroglobulinemia. Oncotarget 2017; 8:112917-112927. [PMID: 29348877 PMCID: PMC5762562 DOI: 10.18632/oncotarget.22872] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 11/17/2017] [Indexed: 12/05/2022] Open
Abstract
Background Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describe these mechanisms. Material and Method MM and WM-derived cell lines, and Waldenström's CD19+ cells were treated using both lenalidomide and pomalidomide. Stable CRBN expressing cells were generated. Results WM-derived cells were resistant to IMid compounds. We demonstrated a modulation of the downstream targets of IRF4, despite low expression of cereblon, and hypothesized IRF4 was the cause for resistance to IMid compounds. We ruled out the role of various IRF4 regulatory mechanisms, and other pathways activating WM tumor cells, such as B cell activators. Conclusion This study demonstrated that mechanisms of resistance to IMid compounds could be not related to cereblon. IRF4 was identified as the potential mechanism of resistance to lenalidomide and pomalidomide in WM. It potentially explains the lesser activity observed in the clinic in WM. Interestingly, some WM patients benefited strongly to lenalidomide and pomalidomide, and future studies will have to describe the indirect mechanisms of IMid compounds in WM, possibly related to an immune-mediated process.
Collapse
Affiliation(s)
- Elisabeth Bertrand
- Univ. Lille, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, JPARC - Centre de Recherche Jean-Pierre AUBERT, Neurosciences et Cancer, Lille, France.,Inserm, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, Lille, France.,Institut pour la Recherche sur le Cancer de Lille, Factors of Persistence of Leukemic Cells Team, Lille, France
| | - Nathalie Jouy
- Univ. Lille, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, JPARC - Centre de Recherche Jean-Pierre AUBERT, Neurosciences et Cancer, Lille, France.,Plateau de Cytométrie, BioImaging Center Lille Nord de France, BICeL Campus Hospitalo-Universitaire, Lille, France
| | - Salomon Manier
- Univ. Lille, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, JPARC - Centre de Recherche Jean-Pierre AUBERT, Neurosciences et Cancer, Lille, France.,Inserm, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, Lille, France.,Service des Maladies du Sang, CHU, Lille, France.,Institut pour la Recherche sur le Cancer de Lille, Factors of Persistence of Leukemic Cells Team, Lille, France
| | | | - Stéphanie Guidez
- Service d'Hématologie et Thérapie Cellulaire, Hôpital La Milétrie, et Faculté de Médecine, CHU, Poitiers, France.,CIC Inserm 1402, CHU, Poitiers, France
| | - Eileen Boyle
- Service des Maladies du Sang, CHU, Lille, France
| | | | - Cécile Tomowiak
- Service d'Hématologie et Thérapie Cellulaire, Hôpital La Milétrie, et Faculté de Médecine, CHU, Poitiers, France.,CIC Inserm 1402, CHU, Poitiers, France
| | | | - Susanna Schraen
- Laboratoire d'Hématologie, Centre de Biologie et Pathologie, CHU, Lille, France
| | - Claude Preudhomme
- Univ. Lille, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, JPARC - Centre de Recherche Jean-Pierre AUBERT, Neurosciences et Cancer, Lille, France.,Inserm, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, Lille, France.,Institut pour la Recherche sur le Cancer de Lille, Factors of Persistence of Leukemic Cells Team, Lille, France.,Laboratoire d'Hématologie, Centre de Biologie et Pathologie, CHU, Lille, France
| | - Bruno Quesnel
- Univ. Lille, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, JPARC - Centre de Recherche Jean-Pierre AUBERT, Neurosciences et Cancer, Lille, France.,Inserm, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, Lille, France.,Service des Maladies du Sang, CHU, Lille, France.,Institut pour la Recherche sur le Cancer de Lille, Factors of Persistence of Leukemic Cells Team, Lille, France
| | - Stéphanie Poulain
- Univ. Lille, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, JPARC - Centre de Recherche Jean-Pierre AUBERT, Neurosciences et Cancer, Lille, France.,Inserm, UMR-S 1172, Factors of Persistence of Leukemic Cells Team, Lille, France.,Institut pour la Recherche sur le Cancer de Lille, Factors of Persistence of Leukemic Cells Team, Lille, France.,Laboratoire d'Hématologie, Centre de Biologie et Pathologie, CHU, Lille, France
| | - Xavier Leleu
- Service d'Hématologie et Thérapie Cellulaire, Hôpital La Milétrie, et Faculté de Médecine, CHU, Poitiers, France.,CIC Inserm 1402, CHU, Poitiers, France
| |
Collapse
|
80
|
Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, Wang Y, Faure P, Szymanski G, Duployez N, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Park S. Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget 2017; 8:105510-105524. [PMID: 29285268 PMCID: PMC5739655 DOI: 10.18632/oncotarget.22299] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 08/26/2017] [Indexed: 11/25/2022] Open
Abstract
Anemia is a frequent cytopenia in myelodysplastic syndromes (MDS) and most patients require red blood cell transfusion resulting in iron overload (IO). Deferasirox (DFX) has become the standard treatment of IO in MDS and it displays positive effects on erythropoiesis. In low risk MDS samples, mechanisms improving erythropoiesis after DFX treatment remain unclear. Herein, we addressed this question by using liquid cultures with iron overload of erythroid precursors treated with low dose of DFX (3μM), which corresponds to DFX 5 mg/kg/day, an unusual dose used for iron chelation. We highlight a decreased apoptosis rate and an increased proportion of cycling cells, both leading to higher proliferation rates. The iron chelation properties of low dose DFX failed to activate the Iron Regulatory Proteins and to support iron depletion, but low dose DFX dampers intracellular reactive oxygen species. Furthermore low concentrations of DFX activate the NF-κB pathway in erythroid precursors triggering anti-apoptotic and anti-inflammatory signals. Establishing stable gene silencing of the Thioredoxin (TRX) 1 genes, a NF-κB modulator, showed that fine-tuning of reactive oxygen species (ROS) levels regulates NF-κB. These results justify a clinical trial proposing low dose DFX in MDS patients refractory to erythropoiesis stimulating agents.
Collapse
Affiliation(s)
- Mathieu Meunier
- CHU Grenoble Alpes, University Clinic of Hematology, Grenoble, France.,Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France
| | - Sarah Ancelet
- Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France
| | | | - Josiane Arnaud
- Unité de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicologie - Pharmacologie, CHU Grenoble Alpes, Grenoble, France
| | - Catherine Garrel
- Unité de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicologie - Pharmacologie, CHU Grenoble Alpes, Grenoble, France
| | - Mylène Pezet
- Plateforme de Microscopie Photonique - Cytométrie en Flux, Institut Albert Bonniot, La Tronche, France
| | - Yan Wang
- Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France
| | - Patrice Faure
- Unité de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicologie - Pharmacologie, CHU Grenoble Alpes, Grenoble, France
| | | | - Nicolas Duployez
- Laboratory of Hematology and Tumor Bank, INSERM UMR-S 1172, Cancer Research Institute of Lille, CHRU of Lille, University Lille Nord de France, Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology and Tumor Bank, INSERM UMR-S 1172, Cancer Research Institute of Lille, CHRU of Lille, University Lille Nord de France, Lille, France
| | - Denis Biard
- CEA, Institut de Biologie François Jacob, SEPIA, Team Cellular Engineering and Human Syndromes, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Benoit Polack
- Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France.,Laboratory of Hematology, CHU Grenoble Alpes, Grenoble, France
| | - Jean-Yves Cahn
- CHU Grenoble Alpes, University Clinic of Hematology, Grenoble, France.,Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France
| | - Jean Marc Moulis
- Université Grenoble Alpes, Laboratory of Fundamental and Applied Bioenergetics, and Environmental and Systems Biology, Grenoble, France.,INSERM U1055, Grenoble, France.,CEA-Grenoble, Bioscience and Biotechnology Institute, Grenoble, France
| | - Sophie Park
- CHU Grenoble Alpes, University Clinic of Hematology, Grenoble, France.,Université Grenoble Alpes, CNRS UMR 5525, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG ThEREx, Grenoble, France
| |
Collapse
|
81
|
Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, Fenneteau O, Petit A, Cuccuini W, Ragu C, Preudhomme C, Mercher T, Sirvent N, Leverger G. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatr Hematol Oncol 2017; 34:425-427. [PMID: 29303660 DOI: 10.1080/08880018.2017.1414905] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, initial leukocyte count, CNS involvement, and complete remission rate (88.9%), as compared to other acute myeloid leukemia (AML) subtypes. AMKL patients had a significantly poorer outcome (5-year overall survival 54% [CI 95% 33%-71%] than children with other AML subtypes (5-year overall survival 73% [CI 95% 68%-77%] p = 0.02). Gender, age, CNS leukemia, hyperleukocytosis, complete remission or cytogenetic subgroups were not significant prognostic factors of disease-free survival. AMKL (excluding Down syndrom) remains an AML subgroup with inferior outcome.
Collapse
Affiliation(s)
- Anne-Charlotte Teyssier
- a Department of Pediatric Onco-Hematology , University Hospital Arnaud de Villeneuve , Montpellier , France
| | - Hélène Lapillonne
- b Hematology Laboratory, Armand Trousseau Hospital, APHP , Paris , France
| | - Marlene Pasquet
- c Department of Pediatric Onco-Hematology , University Hospital Purpan , Toulouse , France
| | - Paola Ballerini
- b Hematology Laboratory, Armand Trousseau Hospital, APHP , Paris , France
| | - André Baruchel
- d Department of Pediatric Hematology , Robert-Debré Hospital, APHP , Paris , France
| | - Stephane Ducassou
- e Department of Pediatric Onco-Hematology , University Hospital , Bordeaux , France
| | - Odile Fenneteau
- f Hematology Laboratory, Robert-Debré Hospital, APHP , Paris , France
| | - Arnaud Petit
- g Department of Pediatric Hematology , Armand Trousseau Hospital, APHP , Paris , France
| | - Wendy Cuccuini
- h Hematology Laboratory, Saint-Louis Hospital, APHP , Paris , France
| | - Christine Ragu
- g Department of Pediatric Hematology , Armand Trousseau Hospital, APHP , Paris , France
| | - Claude Preudhomme
- i U837 INSERM and Hematology Laboratory, University Hospital of Lille , France
| | - Thomas Mercher
- j U985 INSERM, Institut Gustave Roussy , Villejuif , France
| | - Nicolas Sirvent
- a Department of Pediatric Onco-Hematology , University Hospital Arnaud de Villeneuve , Montpellier , France
| | - Guy Leverger
- g Department of Pediatric Hematology , Armand Trousseau Hospital, APHP , Paris , France
| |
Collapse
|
82
|
Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiègue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X. BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia. Oncotarget 2017; 8:57451-57459. [PMID: 28924457 PMCID: PMC5593656 DOI: 10.18632/oncotarget.9917] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2016] [Accepted: 05/12/2016] [Indexed: 12/29/2022] Open
Abstract
Approximately 30% of the patients who fulfil the criteria of Waldenström's macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A- to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile, BACH2, a B-cell transcription factor known to be a tumor suppressor gene, was found to be over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in a WM-related cell line and observed a significant reduction of the clonogenic activity. To the best of our knowledge, we report for the first time a specific gene expression signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 was identified as a candidate gene that may help to understand better the behavior of tumor cells in indolent WM.
Collapse
Affiliation(s)
- Charles Herbaux
- Inserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.,Service des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France
| | | | - Guillemette Marot
- Lille Nord de France University, Equipe Biostatistique, UDSL, Lille, France
| | - Christophe Roumier
- Laboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
| | - Nicolas Poret
- Inserm U837, Team 3, Cancer Research Institute of Lille, Lille, France
| | - Valérie Soenen
- Laboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
| | - Olivier Nibourel
- Laboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
| | | | | | | | - Eileen M Boyle
- Service des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France
| | | | - Aline Renneville
- Laboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
| | - Sabine Tricot
- Département d'Hématologie-Immunologie-Cytogénétique, CH, Valenciennes, France
| | | | - Claude Preudhomme
- Laboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France
| | - Bruno Quesnel
- Inserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.,Service des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France
| | - Stephanie Poulain
- Département d'Hématologie-Immunologie-Cytogénétique, CH, Valenciennes, France
| | - Xavier Leleu
- Service d'Hématolgie et Thérapie cellulaire, Hématologie, CHU, Poitiers, France.,Centre d'Investigation Clinique Inserm, CHU, Poitiers, France
| |
Collapse
|
83
|
Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X. TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clin Cancer Res 2017; 23:6325-6335. [PMID: 28754818 DOI: 10.1158/1078-0432.ccr-17-0007] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2017] [Revised: 06/03/2017] [Accepted: 07/18/2017] [Indexed: 11/16/2022]
Abstract
Purpose:TP53 is a tumor-suppressor gene that functions as a regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little is known regarding TP53 alteration in Waldenstrom's macroglobulinemia (WM).Experimental Design: Here, we have explored the incidence of TP53 alteration using Sanger sequencing and ultradeep-targeted sequencing in 125 WM and 10 immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS), along with the clinical features and the associated genomic landscape using single-nucleotide polymorphism array and mutational landscape in an integrative study.Results: Overall, we have identified alteration of TP53 locus including mutation, deletion, and copy-neutral LOH in 11.2% of WM. TP53 mutation was acquired in 7.3% of patients with WM at diagnosis, being absent in IgM MGUS, and was highly correlated to deletion 17p. No correlation with CXCR4 mutations was observed. Patients with TP53 alteration had a greater number of genomic abnormalities. Importantly, WM with TP53 alteration had a significantly shorter overall survival, particularly in symptomatic WM, and independently of the international prognostic scoring system for Waldenstrom macroglobulinemia (IPSSWM) score. Specific treatment for WM with TP53 may have to be studied. Nutlin-3a-targeted p53 signaling induced cytotoxicity preclinically, along with new compounds such as ibrutinib, PrimaMet, or CP31398 that bypass p53 pathway in WM, paving the path for future treatment-tailored options.Conclusions: Our results highlight the clinical significance of detection of TP53 alteration in WM to determine the prognosis of WM and guide the treatment choice. Clin Cancer Res; 23(20); 6325-35. ©2017 AACR.
Collapse
Affiliation(s)
- Stéphanie Poulain
- Service d'Hématologie- Immunologie- Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France.,Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.,INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Christophe Roumier
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.,INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Elisabeth Bertrand
- INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Aline Renneville
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.,INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Aurélie Caillault-Venet
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Emmanuelle Doye
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Sandrine Geffroy
- INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Sheherazade Sebda
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Olivier Nibourel
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.,INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Morgane Nudel
- Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Charles Herbaux
- Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Loic Renaud
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Cécile Tomowiak
- Service d'Hématologie et Thérapie cellulaire, Centre d'Investigation Clinique, Hôpital de la Milétrie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.,INSERM U1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Stéphanie Guidez
- Service d'Hématologie et Thérapie cellulaire, Centre d'Investigation Clinique, Hôpital de la Milétrie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.,INSERM U1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Sabine Tricot
- Service d'Hématologie- Immunologie- Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France
| | - Catherine Roche-Lestienne
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.,INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Bruno Quesnel
- INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France.,Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Claude Preudhomme
- Laboratoire d'Hématologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.,INSERM UMR 1172, Team 4, Cancer Research Institute of Lille, Lille, France
| | - Xavier Leleu
- Service d'Hématologie et Thérapie cellulaire, Centre d'Investigation Clinique, Hôpital de la Milétrie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France. .,INSERM U1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| |
Collapse
|
84
|
Attias P, Renneville A, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau A, Cassinat B, Feuillard J, Terre C, Delabesse E, Park S, Lejeune S, Chevret S, Ades L, Preudhomme C, Fenaux P. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30382-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
85
|
|
86
|
Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol 2017; 35:1223-1230. [PMID: 28221862 DOI: 10.1200/jco.2016.70.4551] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA) versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acute myeloid leukemia (AML). Patients and Methods Patients age 18 to 59 years old with intermediate- or unfavorable-risk AML in first remission and no identified donor for allogeneic stem-cell transplantation (SCT) were eligible. Two hundred twenty-one patients were randomly assigned to receive three CLARA or three HDAC consolidation cycles. The primary end point was relapse-free survival (RFS). To handle the confounding effect of SCT that could occur in patients with late donor identification, hazard ratios (HRs) of events were adjusted on the time-dependent treatment × SCT interaction term. Results At 2 years, RFS was 58.5% (95% CI, 49% to 67%) in the CLARA arm and 46.5% (95% CI, 37% to 55%) in the HDAC arm. Overall, 110 patients (55 in each arm) received SCT in first remission. On the basis of a multivariable Cox-adjusted treatment × SCT interaction, the HR of CLARA over HDAC before or in absence of SCT was 0.65 (95% CI, 0.43 to 0.98; P = .041). In a sensitivity analysis, when patients who received SCT in first remission were censored at SCT time, 2-year RFS was 53.3% (95% CI, 39% to 66%) in the CLARA arm and 31.0% (95% CI, 19% to 43%) in the HDAC arm (HR, 0.63; 95% CI, 0.41 to 0.98; P = .043). Gain in RFS could be related to the lower cumulative incidence of relapse observed in the CLARA arm versus the HDAC arm (33.9% v 46.4% at 2 years, respectively; cause-specific HR, 0.61; 95% CI, 0.40 to 0.94; P = .025). CLARA cycles were associated with higher hematologic and nonhematologic toxicity than HDAC cycles. Conclusion These results suggest that CLARA might be considered as a new chemotherapy option in younger patients with AML in first remission.
Collapse
Affiliation(s)
- Xavier Thomas
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Stéphane de Botton
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Sylvie Chevret
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Denis Caillot
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Emmanuel Raffoux
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Emilie Lemasle
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Jean-Pierre Marolleau
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Céline Berthon
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Arnaud Pigneux
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Norbert Vey
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Oumedaly Reman
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Marc Simon
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Christian Recher
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Jean-Yves Cahn
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Olivier Hermine
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Sylvie Castaigne
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Karine Celli-Lebras
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Norbert Ifrah
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Claude Preudhomme
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Christine Terré
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Hervé Dombret
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| |
Collapse
|
87
|
Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML. Leuk Res 2017; 56:21-28. [PMID: 28167452 DOI: 10.1016/j.leukres.2017.01.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Revised: 01/03/2017] [Accepted: 01/05/2017] [Indexed: 01/21/2023]
Abstract
In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cumulative incidence of relapse (CIR). Age, cytogenetics, and TET2E2S were independent prognostic factors for disease-free survival (DFS), and favorable effects on outcomes predominated in cytogenetic normal (CN)-AML and younger patients. Using the same cutoff in a validation cohort of 86 CN-AML patients, TET2E2Shigh patients were found to be younger than TET2low patients without a difference in the rate of complete remission. However, TET2E2Shigh patients exhibited a significantly lower CIR (p<10-4). TET2E2S and FLT3-ITD, but not age or NPM1 mutation status were independent prognostic factors for DFS and event-free survival (EFS), while TET2E2S was the sole prognostic factor that we identified for overall survival (OS). In both the intermediate-1 and favorable ELN genetic categories, TET2E2S remained significantly associated with prolonged survival. There was no correlation between TET2E2S status and outcomes in 34 additional AML patients who were unfit for IC. Therefore our results suggest that assessments of TET2 exon 2 splicing status might improve risk stratification in CN-AML patients treated with IC.
Collapse
Affiliation(s)
- Aminetou Mint Mohamed
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France
| | - Marie Balsat
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France
| | - Catherine Koering
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France
| | - Delphine Maucort-Boulch
- Service de Biostatistique, UMR 5558, Laboratoire Biostatistique Santé, Pierre-Bénite, France
| | | | - Lea Payen-Gay
- INSERM, UMR-S1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Meyling Cheok
- Jean-Pierre Aubert Center, INSERM U837, Facteurs de persistance des cellules leucémiques, Institute for Cancer Research in Lille, Genomics Core, 1, Place de Verdun, 59045, Lille Cedex, France
| | - Hussein Mortada
- Centre de Recherche sur le Cancer de Lyon, Inserm, Epissage alternatif et progression tumorale, Lyon, France
| | - Didier Auboeuf
- Centre de Recherche sur le Cancer de Lyon, Inserm, Epissage alternatif et progression tumorale, Lyon, France
| | - Christiane Pinatel
- Centre de Recherche sur le Cancer de Lyon, Inserm, Echappement aux systèmes de sauvegarde et plasticité cellulaire, Lyon, France
| | - Mohamed El-Hamri
- Université Lyon I, Service d'Hématologie, Pavillon Marcel Bérard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Isabelle Tigaud
- Université Lyon I, Cytogénétique, Laboratoire d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Sandrine Hayette
- Université Lyon I, Laboratoire d'Hématologie-Biologie Moléculaire, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Charles Dumontet
- Centre de Recherche sur le Cancer de Lyon, Inserm, Anticorps Anticancer, Lyon, France
| | - Emeline Cros
- Centre de Recherche sur le Cancer de Lyon, Inserm, Anticorps Anticancer, Lyon, France
| | - Pascale Flandrin-Gresta
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France; Université de Saint Etienne, Laboratoire d'Hématologie, CHU de Saint-Etienne, France
| | - Olivier Nibourel
- Jean-Pierre Aubert Center, INSERM U837, Facteurs de persistance des cellules leucémiques, Institute for Cancer Research in Lille, Genomics Core, 1, Place de Verdun, 59045, Lille Cedex, France
| | - Claude Preudhomme
- Jean-Pierre Aubert Center, INSERM U837, Facteurs de persistance des cellules leucémiques, Institute for Cancer Research in Lille, Genomics Core, 1, Place de Verdun, 59045, Lille Cedex, France
| | - Xavier Thomas
- Université Lyon I, Service d'Hématologie, Pavillon Marcel Bérard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Franck-Emmanuel Nicolini
- Université Lyon I, Service d'Hématologie, Pavillon Marcel Bérard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Françoise Solly
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France; Université de Saint Etienne, Laboratoire d'Hématologie, CHU de Saint-Etienne, France
| | - Denis Guyotat
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France; Institut de Cancérologie de la Loire, CHU de Saint-Etienne, Saint Priest en Jarez, France
| | - Lydia Campos
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France; Université de Saint Etienne, Laboratoire d'Hématologie, CHU de Saint-Etienne, France
| | - Mauricette Michallet
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France; Université Lyon I, Service d'Hématologie, Pavillon Marcel Bérard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Antony Ceraulo
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France
| | - Franck Mortreux
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France.
| | - Eric Wattel
- Université Lyon 1, CNRS UMR5239, Oncovirologie et Biothérapies, Faculté de Médecine Lyon Sud, ENS - HCL, Pierre Bénite, France; Université Lyon I, Service d'Hématologie, Pavillon Marcel Bérard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
| |
Collapse
|
88
|
Duléry R, Nibourel O, Gauthier J, Elsermans V, Behal H, Coiteux V, Magro L, Renneville A, Marceau A, Boyer T, Quesnel B, Preudhomme C, Duhamel A, Yakoub-Agha I. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant 2017; 52:539-543. [PMID: 28067876 DOI: 10.1038/bmt.2016.318] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2016] [Revised: 09/22/2016] [Accepted: 10/05/2016] [Indexed: 11/09/2022]
Abstract
The monitoring of the minimal residual disease by Wilms' tumor 1 expression (MRDWT1) is a standardized test, which can be used in over 80% of patients with AML. To investigate the prognostic value of MRDWT1 in patients undergoing allogeneic stem cell transplantation (allo-SCT) for AML, MRDWT1 was monitored 3 months after transplantation in 139 patients. MRDWT1 positivity did not lead to any therapeutic intervention. Median follow-up was 39.3 (6.4-99.8) months. Patients with positive MRDWT1 at 3 months experienced more often post-transplant relapse (27/30, 90%) than those with negative MRDWT1 (16/109, 14.7%) (P<0.0001). Similarly, a shorter 3-year event-free survival (EFS) was observed in MRDWT1-positive patients (10% vs 72.3% in MRDWT1-negative patients, P<0.0001). The correlation between relapse and MRDWT1 was stronger in blood than in bone marrow samples. Multivariate analysis confirmed the detrimental role of 3-month positive MRDWT1 for relapse (hazard ratio (HR): 15.42; 95% confidence interval (CI): 7.53-31.59; P<0.0001) and EFS (HR: 10.71; 95% CI: 5.41-21.21; P<0.0001). Interestingly, 3-month chimerism was less predictive of relapse than positive MRDWT1. In conclusion, our results demonstrate the usefulness of peripheral blood MRDWT1 monitoring in identifying very high-risk patients, who could benefit from an early preemptive treatment, and those who do not need such an intervention.
Collapse
Affiliation(s)
- R Duléry
- Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.,University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France
| | - O Nibourel
- University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.,Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - J Gauthier
- Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.,University of Lille Nord de France, Lille, France
| | - V Elsermans
- University of Lille Nord de France, Lille, France.,Laboratory of Immunology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - H Behal
- University of Lille Nord de France, Lille, France.,Department of Biostatistics, CHRU Lille, Lille, France
| | - V Coiteux
- Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.,University of Lille Nord de France, Lille, France
| | - L Magro
- Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.,University of Lille Nord de France, Lille, France
| | - A Renneville
- University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.,Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - A Marceau
- University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.,Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - T Boyer
- University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.,Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - B Quesnel
- Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.,University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France
| | - C Preudhomme
- University of Lille Nord de France, Lille, France.,Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.,Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - A Duhamel
- University of Lille Nord de France, Lille, France.,Laboratory of Immunology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - I Yakoub-Agha
- Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.,University of Lille Nord de France, Lille, France.,LIRC U995, Lille, France
| |
Collapse
|
89
|
Chauveau A, Nibourel O, Tondeur S, Luque Paz D, Mansier O, Paul F, Wemeau M, Preudhomme C, Lippert E, Ugo V. Absence of CALR mutations in JAK2-negative polycythemia. Haematologica 2017; 102:e15-e16. [PMID: 27758825 PMCID: PMC5210252 DOI: 10.3324/haematol.2016.154799] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Affiliation(s)
| | | | | | | | | | | | | | | | - Eric Lippert
- CHRU Brest, Service d'Hématologie Biologique, France
| | - Valérie Ugo
- CHU Angers, Laboratoire d'Hématologie, France
| |
Collapse
|
90
|
Salson M, Giraud M, Caillault A, Grardel N, Duployez N, Ferret Y, Duez M, Herbert R, Rocher T, Sebda S, Quief S, Villenet C, Figeac M, Preudhomme C. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones. Leuk Res 2016; 53:1-7. [PMID: 27930944 DOI: 10.1016/j.leukres.2016.11.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 10/28/2016] [Accepted: 11/11/2016] [Indexed: 01/22/2023]
Abstract
Minimal residual disease (MRD) is known to be an independent prognostic factor in patients with acute lymphoblastic leukemia (ALL). High-throughput sequencing (HTS) is currently used in routine practice for the diagnosis and follow-up of patients with hematological neoplasms. In this retrospective study, we examined the role of immunoglobulin/T-cell receptor-based MRD in patients with ALL by HTS analysis of immunoglobulin H and/or T-cell receptor gamma chain loci in bone marrow samples from 11 patients with ALL, at diagnosis and during follow-up. We assessed the clinical feasibility of using combined HTS and bioinformatics analysis with interactive visualization using Vidjil software. We discuss the advantages and drawbacks of HTS for monitoring MRD. HTS gives a more complete insight of the leukemic population than conventional real-time quantitative PCR (qPCR), and allows identification of new emerging clones at each time point of the monitoring. Thus, HTS monitoring of Ig/TR based MRD is expected to improve the management of patients with ALL.
Collapse
Affiliation(s)
- Mikaël Salson
- Univ. Lille, CNRS, Centrale Lille, Inria, UMR 9189 - CRIStAL - Centre de Recherche en Informatique Signal et Automatique de Lille, F-59000 Lille, France.
| | - Mathieu Giraud
- Univ. Lille, CNRS, Centrale Lille, Inria, UMR 9189 - CRIStAL - Centre de Recherche en Informatique Signal et Automatique de Lille, F-59000 Lille, France.
| | - Aurélie Caillault
- Univ. Lille, CHU Lille, Department of Hematology, F-59000 Lille, France.
| | - Nathalie Grardel
- Univ. Lille, CHU Lille, Department of Hematology, F-59000 Lille, France.
| | - Nicolas Duployez
- Univ. Lille, CHU Lille, Department of Hematology, F-59000 Lille, France
| | - Yann Ferret
- Univ. Lille, CHU Lille, Department of Hematology, F-59000 Lille, France
| | - Marc Duez
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Ryan Herbert
- Univ. Lille, CNRS, Centrale Lille, Inria, UMR 9189 - CRIStAL - Centre de Recherche en Informatique Signal et Automatique de Lille, F-59000 Lille, France
| | - Tatiana Rocher
- Univ. Lille, CNRS, Centrale Lille, Inria, UMR 9189 - CRIStAL - Centre de Recherche en Informatique Signal et Automatique de Lille, F-59000 Lille, France
| | - Shéhérazade Sebda
- Univ. Lille, Plate-forme de génomique fonctionnelle et structurale, F-59000 Lille, France
| | - Sabine Quief
- Univ. Lille, Plate-forme de génomique fonctionnelle et structurale, F-59000 Lille, France
| | - Céline Villenet
- Univ. Lille, Plate-forme de génomique fonctionnelle et structurale, F-59000 Lille, France
| | - Martin Figeac
- Univ. Lille, Plate-forme de génomique fonctionnelle et structurale, F-59000 Lille, France; Univ. Lille, CHU Lille, Cellule bioinformatique, plateau commun de séquençage, F-59000 Lille, France
| | - Claude Preudhomme
- Univ. Lille, CHU Lille, Department of Hematology, F-59000 Lille, France.
| |
Collapse
|
91
|
Duployez N, Lejeune S, Renneville A, Preudhomme C. Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Rev Hematol 2016; 9:1189-1202. [DOI: 10.1080/17474086.2016.1257936] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
92
|
Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol 2016; 35:185-193. [PMID: 28056203 DOI: 10.1200/jco.2016.67.1875] [Citation(s) in RCA: 193] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed the question of whether NPM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit. Patients and Methods Among 229 patients with NPM1m who were treated in the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 patients in first remission. Patients with nonfavorable AML according to the European LeukemiaNet (ELN) classification were eligible for ASCT in first remission. Results After induction therapy, patients who did not achieve a 4-log reduction in NPM1m peripheral blood-MRD (PB-MRD) had a higher cumulative incidence of relapse (subhazard ratio [SHR], 5.83; P < .001) and a shorter overall survival (OS; hazard ratio [HR], 10.99; P < .001). In multivariable analysis, an abnormal karyotype, the presence of FLT3-internal tandem duplication (ITD), and a < 4-log reduction in PB-MRD were significantly associated with a higher relapse incidence and shorter OS. In the subset of patients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD, but not FLT3-ITD allelic ratio, remained of significant prognostic value. In these patients with nonfavorable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved by ASCT in those with a < 4-log reduction in PB-MRD. This benefit was not observed in those with a > 4-log reduction in PB-MRD, with a significant interaction between ASCT effect and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively). Conclusion Our study supports the strong prognostic significance of early NPM1m PB-MRD, independent of the cytogenetic and molecular context. Moreover, NPM1m PB-MRD may be used as a predictive factor for ASCT indication.
Collapse
Affiliation(s)
- Marie Balsat
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Aline Renneville
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Xavier Thomas
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Stéphane de Botton
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Denis Caillot
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Alice Marceau
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Emilie Lemasle
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Jean-Pierre Marolleau
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Olivier Nibourel
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Céline Berthon
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Emmanuel Raffoux
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Arnaud Pigneux
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Céline Rodriguez
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Norbert Vey
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Jean-Michel Cayuela
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Sandrine Hayette
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Thorsten Braun
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Marie Magdeleine Coudé
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Christine Terre
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Karine Celli-Lebras
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Hervé Dombret
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Claude Preudhomme
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Nicolas Boissel
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| |
Collapse
|
93
|
Bruzzoni-Giovanelli H, González JR, Sigaux F, Villoutreix BO, Cayuela JM, Guilhot J, Preudhomme C, Guilhot F, Poyet JL, Rousselot P. Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. Oncotarget 2016; 6:36269-77. [PMID: 26474455 PMCID: PMC4742176 DOI: 10.18632/oncotarget.5915] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 09/14/2015] [Indexed: 12/22/2022] Open
Abstract
Little is known about inherited factors associated with the risk of developing chronic myelogenous leukemia (CML). We used a dedicated DNA chip containing 16 561 single nucleotide polymorphisms (SNPs) covering 1 916 candidate genes to analyze 437 CML patients and 1 144 healthy control individuals. Single SNP association analysis identified 139 SNPs that passed multiple comparisons (1% false discovery rate). The HDAC9, AVEN, SEMA3C, IKBKB, GSTA3, RIPK1 and FGF2 genes were each represented by three SNPs, the PSM family by four SNPs and the SLC15A1 gene by six. Haplotype analysis showed that certain combinations of rare alleles of these genes increased the risk of developing CML by more than two or three-fold. A classification tree model identified five SNPs belonging to the genes PSMB10, TNFRSF10D, PSMB2, PPARD and CYP26B1, which were associated with CML predisposition. A CML-risk-allele score was created using these five SNPs. This score was accurate for discriminating CML status (AUC: 0.61, 95%CI: 0.58-0.64). Interestingly, the score was associated with age at diagnosis and the average number of risk alleles was significantly higher in younger patients. The risk-allele score showed the same distribution in the general population (HapMap CEU samples) as in our control individuals and was associated with differential gene expression patterns of two genes (VAPA and TDRKH). In conclusion, we describe haplotypes and a genetic score that are significantly associated with a predisposition to develop CML. The SNPs identified will also serve to drive fundamental research on the putative role of these genes in CML development.
Collapse
Affiliation(s)
- Heriberto Bruzzoni-Giovanelli
- Université Paris Diderot, Sorbonne Paris Cité UMRS 1160 INSERM, Paris, France.,Centre d'Investigations Cliniques 9504 INSERM-AP-HP Hôpital Saint-Louis, Paris, France
| | - Juan R González
- Centre de Recerca en Epidemiologia Ambiental (CREAL), Barcelona, Spain.,Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Spain Centre de Recerca en Epidemiologia Ambiental (CREAL), Barcelona, Spain
| | - François Sigaux
- Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Bruno O Villoutreix
- Université Paris Diderot, Sorbonne Paris Cité UMRS 973 Inserm, Paris, France/ Inserm, U973, Paris, France
| | - Jean Michel Cayuela
- Laboratoire Central d'Hématologie, Hôpital Saint Louis, Paris, France.,EA3518, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | | - Claude Preudhomme
- Laboratoire d'Hématologie, Inserm, U837, CHRU, Lille, France/Université de Lille Nord, Institut de Recherche sur le Cancer de Lille, Lille, France
| | | | - Jean-Luc Poyet
- Université Paris Diderot, Sorbonne Paris Cité UMRS 1160 INSERM, Paris, France
| | - Philippe Rousselot
- Service d'Hématologie et d'Oncologie, Hôpital Mignot, Université Versailles, Saint-Quentin-en-Yvelines, France
| |
Collapse
|
94
|
Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia 2016; 31:555-564. [PMID: 27686867 DOI: 10.1038/leu.2016.265] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 08/18/2016] [Accepted: 08/24/2016] [Indexed: 01/08/2023]
Abstract
Recent advances in genomic technologies have revolutionized acute myeloid leukemia (AML) understanding by identifying potential novel actionable genomic alterations. Consequently, current risk stratification at diagnosis not only relies on cytogenetics, but also on the inclusion of several of these abnormalities. Despite this progress, AML remains a heterogeneous and complex malignancy with variable response to current therapy. Although copy-number alterations (CNAs) are accepted prognostic markers in cancers, large-scale genomic studies aiming at identifying specific prognostic CNA-based markers in AML are still lacking. Using 367 AML, we identified four recurrent CNA on chromosomes 11 and 21 that predicted outcome even after adjusting for standard prognostic risk factors and potentially delineated two new subclasses of AML with poor prognosis. ERG amplification, the most frequent CNA, was related to cytarabine resistance, a cornerstone drug of AML therapy. These findings were further validated in The Cancer Genome Atlas data. Our results demonstrate that specific CNA are of independent prognostic relevance, and provide new molecular information into the genomic basis of AML and cytarabine response. Finally, these CNA identified two potential novel risk groups of AML, which when confirmed prospectively, may improve the clinical risk stratification and potentially the AML outcome.
Collapse
Affiliation(s)
- O Nibourel
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - S Guihard
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| | - C Roumier
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - N Pottier
- CHU Lille University Hospital, Department of Biochemistry and Molecular Biology, Lille, France
| | - C Terre
- Hospital of Versailles, Department of Hematology, Chesnay, France
| | - A Paquet
- University Côte d'Azur, CNRS Institute of Molecular and Cellular Pharmacology, Sophia-Antipolis, Nice, France
| | - P Peyrouze
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| | - S Geffroy
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - S Quentin
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - A Alberdi
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - R B Abdelali
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - A Renneville
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - C Demay
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - K Celli-Lebras
- University Paris 7, Department of Hematology, Paris, France
| | - P Barbry
- University Côte d'Azur, CNRS Institute of Molecular and Cellular Pharmacology, Sophia-Antipolis, Nice, France
| | - B Quesnel
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| | - S Castaigne
- Hospital of Versailles, Department of Hematology, Chesnay, France
| | - H Dombret
- University Paris 7, Department of Hematology, Paris, France
| | - J Soulier
- University Paris Diderot, INSERM U944 Saint-Louis Hospital, Department of Hematology, Paris, France
| | - C Preudhomme
- CHU Lille University Hospital, Department of Hematology, Lille, France
| | - M H Cheok
- INSERM UMR-S1172, Institute for Cancer Research of Lille, Factors of Leukemia Cell Persistance, Lille Cedex, France
| |
Collapse
|
95
|
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget 2016; 6:42345-53. [PMID: 26486081 PMCID: PMC4747230 DOI: 10.18632/oncotarget.5645] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 10/02/2015] [Indexed: 12/18/2022] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be determined which molecular markers are the most suitable for MRD monitoring. Recent advances in next-generation sequencing (NGS) have provided the opportunity to use multiple molecular markers. In this study, we used NGS technology to assess MRD in 31 AML patients enrolled in the ALFA-0701 trial and harboring NPM1 mutations associated to IDH1/2 or DNMT3A mutations. NPM1 mutation-based MRD monitoring was performed by RTqPCR. IDH1/2 and DNMT3A mutations were quantified by NGS using an Ion Torrent Proton instrument with high coverage (2 million reads per sample). The monitoringof IDH1/2 mutations showed that these mutations were reliable MRD markers that allowed the prediction of relapse in the majority of patients. Moreover, IDH1/2 mutation status predicted relapse or disease evolution in 100% of cases if we included the patient who developed myelodysplastic syndrome. In contrast, DNMT3A mutations were not correlated to the disease status, as we found that a preleukemic clone with DNMT3A mutation persisted in 40% of the patients who were in complete remission, reflecting the persistence of clonal hematopoiesis.
Collapse
Affiliation(s)
- Houria Debarri
- Hematology Department, Lille University Hospital, Lille, France.,Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France
| | - Delphine Lebon
- Hematology Department, Amiens University Hospital, Amiens, France
| | - Christophe Roumier
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Meyling Cheok
- UMR-S 1172, Team 3, INSERM, Lille, France.,Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Alice Marceau-Renaut
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Olivier Nibourel
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Sandrine Geffroy
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Nathalie Helevaut
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France
| | | | - Bérengère Gruson
- Hematology Department, Amiens University Hospital, Amiens, France
| | - Claude Gardin
- Hematology Department, Avicenne Hospital, APHP, University Paris 13, Bobigny, France
| | | | - Shéhérazade Sebda
- Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Martin Figeac
- Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Céline Berthon
- Hematology Department, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Bruno Quesnel
- Hematology Department, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Nicolas Boissel
- Hematology Department, Saint-Louis Hospital, APHP, Paris, France
| | | | - Hervé Dombret
- Hematology Department, Saint-Louis Hospital, APHP, Paris, France
| | - Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Claude Preudhomme
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| |
Collapse
|
96
|
Charpentier A, Lebreton A, Rauch A, Bauters A, Trillot N, Nibourel O, Tintillier V, Wemeau M, Demory JL, Preudhomme C, Jude B, Lecompte T, Cambier N, Susen S. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. Haematologica 2016; 101:e365-8. [PMID: 27247323 DOI: 10.3324/haematol.2016.144279] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Agnès Charpentier
- Groupement des Hôpitaux de l'Institut Catholique de Lille, Service d'Hématologie Biologique, Université Catholique de Lille, Lomme, France
| | - Aurélien Lebreton
- Centre Hospitalier Universitaire Clermont-Ferrand Estaing, Service d'Hématologie Biologique, Clermont-Ferrand, France Faculté de Médecine, Université de Genève, Geneva Platelet Group, Geneva, Switzerland
| | - Antoine Rauch
- Centre Hospitalier Universitaire de Lille, Laboratoire d'Hématologie-transfusion, France INSERM UMR 1011, Université de Lille 2, Faculté de Médecine, France; EGID, Institut Pasteur de Lille, France
| | - Anne Bauters
- Centre Hospitalier Universitaire de Lille, Laboratoire d'Hématologie-transfusion, France
| | - Nathalie Trillot
- Centre Hospitalier Universitaire de Lille, Laboratoire d'Hématologie-transfusion, France
| | - Oliver Nibourel
- Centre Hospitalier Universitaire de Lille, Centre de Biologie Pathologie, Laboratoire d'Hématologie, France
| | - Véronique Tintillier
- Centre Hospitalier Universitaire de Lille, Laboratoire d'Hématologie-transfusion, France
| | - Mathieu Wemeau
- Centre Hospitalier Universitaire de Lille, Service des Maladies du Sang, France
| | - Jean-Loup Demory
- Groupement des Hôpitaux de l'Institut Catholique de Lille, Service d'Hématologie Biologique, Université Catholique de Lille, Lomme, France Groupement des Hôpitaux de l'Institut Catholique de Lille, Service d'Hématologie, Université Catholique de Lille, France
| | - Claude Preudhomme
- Centre Hospitalier Universitaire de Lille, Centre de Biologie Pathologie, Laboratoire d'Hématologie, France
| | - Brigitte Jude
- Centre Hospitalier Universitaire de Lille, Laboratoire d'Hématologie-transfusion, France INSERM UMR 1011, Université de Lille 2, Faculté de Médecine, France; EGID, Institut Pasteur de Lille, France
| | - Thomas Lecompte
- Faculté de Médecine, Université de Genève, Geneva Platelet Group, Geneva, Switzerland Hôpitaux Universitaires de Genève, Service d'Hématologie, Geneva, Switzerland
| | - Nathalie Cambier
- Groupement des Hôpitaux de l'Institut Catholique de Lille, Service d'Hématologie, Université Catholique de Lille, France
| | - Sophie Susen
- Centre Hospitalier Universitaire de Lille, Laboratoire d'Hématologie-transfusion, France INSERM UMR 1011, Université de Lille 2, Faculté de Médecine, France; EGID, Institut Pasteur de Lille, France
| |
Collapse
|
97
|
Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica 2016; 101:918-25. [PMID: 27229713 DOI: 10.3324/haematol.2015.140988] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 05/26/2016] [Indexed: 11/09/2022] Open
Abstract
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes of patients, all of them having the characteristics of this subset of lower-risk myelodysplastic syndrome, if randomly treated with azacitidine alone or azacitidine combined with epoetin-β. High-resolution cytogenetics and gene mutation analysis were performed at entry. The primary study endpoint was the achievement of red blood cell transfusion independence after six cycles. Ninety-eight patients were randomised (49 in each arm). Median age was 72 years. In an intention to treat analysis, transfusion independence was obtained after 6 cycles in 16.3% versus 14.3% of patients in the azacitidine and azacitidine plus epoetin-β arms, respectively (P=1.00). Overall erythroid response rate (minor and major responses according to IWG 2000 criteria) was 34.7% vs. 24.5% in the azacitidine and azacitidine plus epoetin-β arms, respectively (P=0.38). Mutations of the SF3B1 gene were the only ones associated with a significant erythroid response, 29/59 (49%) versus 6/27 (22%) in SF3B1 mutated and unmutated patients, respectively, P=0.02. Detection of at least one "epigenetic mutation" and of an abnormal single nucleotide polymorphism array profile were the only factors associated with significantly poorer overall survival by multivariate analysis. The transfusion independence rate observed with azacitidine in this lower-risk population, but resistant to erythropoietic stimulating agents, was lower than expected, with no observed benefit of added epoetin, (clinicaltrials.gov identifier: 01015352).
Collapse
Affiliation(s)
- Sylvain Thépot
- Service d'Hématologie Clinique, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), and Université Paris 13, Bobigny, France
| | | | - Sylvie Chevret
- Service de biostatistique et information médicale, Hôpital Saint-Louis, AP-HP and Université Paris 7, France
| | | | - Odile Beyne-Rauzy
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Toulouse, France
| | - Thomas Prébet
- Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - Sophie Park
- Service d'Hématologie Clinique, Hôpital Cochin, AP-HP and Université Paris 5, France
| | | | | | - Stéphane Cheze
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| | - Gérard Tertian
- Service de médecine interne, Hôpital du kremlin-Bicetre, AP-HP and Université Paris, France
| | - Bachra Choufi
- Service d'Hématologie Clinique, Hôpital de Boulogne sur mer, France
| | - Laurence Legros
- Service d'Hématologie, Centre Hospitalier Universitaire, Nice, France
| | - Jean Noel Bastié
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Dijon, France
| | - Jacques Delaunay
- Service d'Hématologie, Centre Hospitalier Universitaire, Nantes, France
| | - Marie Pierre Chaury
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Limoges, France
| | - Laurence Sanhes
- Service d'Hématologie, Centre Hospitalier, Perpignan, France
| | - Eric Wattel
- Service d'Hématologie, Hôpital Universitaire Lyon Sud, Lyon, France
| | - Francois Dreyfus
- Service d'Hématologie Clinique, Hôpital Cochin, AP-HP and Université Paris 5, France
| | - Norbert Vey
- Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - Fatiha Chermat
- Groupe francophone des Myélodysplasies, Hôpital Saint-Louis, AP-HP, France
| | | | - Pierre Fenaux
- Service d'Hématologie Clinique senior, Hôpital Saint-Louis, AP-HP and Université Paris 7, France
| | - Claude Gardin
- Service d'Hématologie Clinique, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), and Université Paris 13, Bobigny, France
| | | |
Collapse
|
98
|
Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood 2016; 127:2451-9. [PMID: 26980726 PMCID: PMC5457131 DOI: 10.1182/blood-2015-12-688705] [Citation(s) in RCA: 177] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Accepted: 03/08/2016] [Indexed: 12/26/2022] Open
Abstract
Acute myeloid leukemia (AML) with t(8;21) or inv(16) have been recognized as unique entities within AML and are usually reported together as core binding factor AML (CBF-AML). However, there is considerable clinical and biological heterogeneity within this group of diseases, and relapse incidence reaches up to 40%. Moreover, translocations involving CBFs are not sufficient to induce AML on its own and the full spectrum of mutations coexisting with CBF translocations has not been elucidated. To address these issues, we performed extensive mutational analysis by high-throughput sequencing in 215 patients with CBF-AML enrolled in the Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor Acute Myeloid Leukemia and Treating Patients with Childhood Acute Myeloid Leukemia with Interleukin-2 trials (age, 1-60 years). Mutations in genes activating tyrosine kinase signaling (including KIT, N/KRAS, and FLT3) were frequent in both subtypes of CBF-AML. In contrast, mutations in genes that regulate chromatin conformation or encode members of the cohesin complex were observed with high frequencies in t(8;21) AML (42% and 18%, respectively), whereas they were nearly absent in inv(16) AML. High KIT mutant allele ratios defined a group of t(8;21) AML patients with poor prognosis, whereas high N/KRAS mutant allele ratios were associated with the lack of KIT or FLT3 mutations and a favorable outcome. In addition, mutations in epigenetic modifying or cohesin genes were associated with a poor prognosis in patients with tyrosine kinase pathway mutations, suggesting synergic cooperation between these events. These data suggest that diverse cooperating mutations may influence CBF-AML pathophysiology as well as clinical behavior and point to potential unique pathogenesis of t(8;21) vs inv(16) AML.
Collapse
MESH Headings
- Adolescent
- Adult
- Alleles
- Cell Cycle Proteins/genetics
- Child
- Child, Preschool
- Chromatin/genetics
- Chromatin/ultrastructure
- Chromosomal Proteins, Non-Histone/genetics
- Chromosome Inversion
- Chromosomes, Human, Pair 16/genetics
- Chromosomes, Human, Pair 21/genetics
- Chromosomes, Human, Pair 8/genetics
- Core Binding Factor Alpha 2 Subunit/genetics
- Core Binding Factors/genetics
- DNA Mutational Analysis
- DNA, Neoplasm/genetics
- Female
- Genetic Association Studies
- High-Throughput Nucleotide Sequencing
- Humans
- Infant
- Leukemia, Myeloid, Acute/genetics
- Male
- Middle Aged
- Mutation
- Oncogene Proteins, Fusion/genetics
- Prognosis
- RUNX1 Translocation Partner 1 Protein
- Translocation, Genetic
- Young Adult
- Cohesins
Collapse
Affiliation(s)
- Nicolas Duployez
- Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, Lille, France
| | - Alice Marceau-Renaut
- Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, Lille, France
| | - Nicolas Boissel
- Department of Hematology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Arnaud Petit
- Department of Pediatric Hematology and Oncology, Trousseau Hospital, AP-HP, Paris, France
| | - Maxime Bucci
- Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| | - Sandrine Geffroy
- Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, Lille, France
| | | | - Aline Renneville
- Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, Lille, France
| | - Christine Ragu
- Department of Pediatric Hematology and Oncology, Trousseau Hospital, AP-HP, Paris, France
| | - Martin Figeac
- Functional and Structural Genomic Platform, Lille University, Lille, France
| | - Karine Celli-Lebras
- Department of Hematology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | | | - Jean-Baptiste Micol
- Department of Hematology, Gustave Roussy Institute, INSERM UMR 1170, Villejuif, France; Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY
| | - Omar Abdel-Wahab
- Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY
| | | | - Norbert Ifrah
- Department of Hematology, CHU Angers, Angers, France; and
| | - Hervé Dombret
- Department of Hematology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Guy Leverger
- Department of Pediatric Hematology and Oncology, Trousseau Hospital, AP-HP, Paris, France
| | - Eric Jourdan
- Department of Hematology, CHU Nîmes, Nîmes, France
| | - Claude Preudhomme
- Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Cancer Research Institute, INSERM Unité Mixte de Recherche (UMR)-S 1172, Lille, France
| |
Collapse
|
99
|
Latger-Cannard V, Philippe C, Bouquet A, Baccini V, Alessi MC, Ankri A, Bauters A, Bayart S, Cornillet-Lefebvre P, Daliphard S, Mozziconacci MJ, Renneville A, Ballerini P, Leverger G, Sobol H, Jonveaux P, Preudhomme C, Nurden P, Lecompte T, Favier R. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J Rare Dis 2016; 11:49. [PMID: 27112265 PMCID: PMC4845427 DOI: 10.1186/s13023-016-0432-0] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Accepted: 04/18/2016] [Indexed: 11/20/2022] Open
Abstract
Background Less than 50 patients with FPD/AML (OMIM 601309) have been reported as of today and there may an underestimation. The purpose of this study was to describe the natural history, the haematological features and the genotype-phenotype correlations of this entity in order to, first, screen it better and earlier, before leukaemia occurrence and secondly to optimize appropriate monitoring and treatment, in particular when familial stem cell transplantation is considered. Methods We have investigated 41 carriers of RUNX1 alteration belonging to nine unrelated French families with FPD/AML and two syndromic patients, registered in the French network on rare platelet disorders from 2005 to 2015. Results Five missense, one non-sense, three frameshift mutations and two large deletions involving several genes including RUNX1 were evidenced. The history of familial leukaemia was suggestive of FPD/AML in seven pedigrees, whereas an autosomal dominant pattern of lifelong thrombocytopenia was the clinical presentation of two. Additional syndromic features characterized two large sporadic deletions. Bleeding tendency was mild and thrombocytopenia moderate (>50 x109/L), with normal platelet volume. A functional platelet defect consistent with a δ-granule release defect was found in ten patients regardless of the type of RUNX1 alteration. The incidence of haematological malignancies was higher when the mutated RUNX1 allele was likely to cause a dominant negative effect (19/34) in comparison with loss of function alleles (3/9). A normal platelet count does not rule out the diagnosis of FPD/AML, since the platelet count was found normal for three mutated subjects, a feature that has a direct impact in the search for a related donor in case of allogeneic haematopoietic stem cell transplantation. Conclusions Platelet dysfunction suggestive of defective δ-granule release could be of values for the diagnosis of FPD/AML particularly when the clinical presentation is an autosomal dominant thrombocytopenia with normal platelet size in the absence of familial malignancies. The genotype-phenotype correlations might be helpful in genetic counselling and appropriate optimal therapeutic management.
Collapse
Affiliation(s)
- Veronique Latger-Cannard
- Service d'Hématologie Biologique, Centre Hospitalier Universitaire de Nancy, Nancy, France.,Centre de Compétence Nord-Est des Pathologies Plaquettaires (CCPP), Nancy, France
| | - Christophe Philippe
- Laboratoire de Génétique, Centre Hospitalier Universitaire de Nancy, Nancy, France
| | - Alexandre Bouquet
- Service d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Veronique Baccini
- Laboratoire d'Hématologie, Hôpital La Timone, Marseille, France.,Centre de Référence des Pathologies Plaquettaires (CRPP), Hôpital La Timone, Marseille, France
| | - Marie-Christine Alessi
- Laboratoire d'Hématologie, Hôpital La Timone, Marseille, France.,Centre de Référence des Pathologies Plaquettaires (CRPP), Hôpital La Timone, Marseille, France
| | - Annick Ankri
- Assistance Publique-Hôpitaux de Paris, Laboratoire d'Hématologie, La Pitié Salpetrière, Paris, France
| | - Anne Bauters
- Centre de Compétence Nord-Est des Pathologies Plaquettaires (CCPP), Nancy, France.,Service d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Sophie Bayart
- Centre Régional de Traitement des Hémophiles, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | | | - Sylvie Daliphard
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire Robert Debré, Reims, France
| | - Marie-Joelle Mozziconacci
- Département de Biopathologie, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
| | - Aline Renneville
- Service d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Paola Ballerini
- Assistance Publique-Hôpitaux de Paris, Département d'Hématologie, Hôpital Armand Trousseau, Paris, France.,Centre de Référence des Pathologies Plaquettaires (CRPP), Hôpital La Timone, Marseille, France
| | - Guy Leverger
- Assistance Publique-Hôpitaux de Paris, Département d'Hématologie, Hôpital Armand Trousseau, Paris, France.,Centre de Référence des Pathologies Plaquettaires (CRPP), Hôpital La Timone, Marseille, France
| | - Hagay Sobol
- Département de Biopathologie, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
| | - Philippe Jonveaux
- Laboratoire de Génétique, Centre Hospitalier Universitaire de Nancy, Nancy, France
| | - Claude Preudhomme
- Service d'Hématologie Biologique, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Paquita Nurden
- Laboratoire d'Hématologie, Hôpital La Timone, Marseille, France.,Centre de Référence des Pathologies Plaquettaires (CRPP), Hôpital La Timone, Marseille, France
| | - Thomas Lecompte
- Service d'Hématologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.,Faculté de Médecine, Université de Genève, Geneva, Switzerland
| | - Remi Favier
- Assistance Publique-Hôpitaux de Paris, Département d'Hématologie, Hôpital Armand Trousseau, Paris, France. .,Inserm U1170, Villejuif, France. .,Centre de Référence des Pathologies Plaquettaires (CRPP), Hôpital La Timone, Marseille, France. .,Service d'Hématologie Biologique, Hôpital d'enfants Armand Trousseau, 26 Avenue du Dr Netter, 75012, Paris, France.
| |
Collapse
|
100
|
Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. The Lancet Haematology 2016; 3:e186-95. [DOI: 10.1016/s2352-3026(15)00247-1] [Citation(s) in RCA: 264] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 11/03/2015] [Accepted: 11/04/2015] [Indexed: 01/07/2023]
|